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Abstract
Progress has been made in using human serum albumin nanoparticles (HSAPs) as carrier
systems for targeted treatment of cancer. Human serum albumin (HSA), the most abundant
human blood protein, can form HSAPs via a desolvation and crosslinking method, with the size
of the HSAPs having crucial importance for drug loading and in vivo performance. Gold
nanoparticles have also gained medicinal attention due to their ability to absorb near-infrared
(NIR) light. These relatively non-toxic particles offer combinational therapy via imaging and
photothermal therapy (PPTT) capabilities.
A desolvation and crosslinking approach was employed to encapsulate gold nanoparticles
(AuNPs), hollow gold nanoshells (AuNSs), and gold nanorods (AuNRs), into efficiently sized
HSAPs for future tumor heat ablation via PPTT. The AuNR-HSAPs, AuNP-HSAPs and AuNSHSAPs had average particle diameters of 222 ± 5, 195 ± 9 and 156 ± 15, respectively.
We simultaneously encapsulated AuNRs and the anticancer drug paclitaxel (PAC),
forming PAC-AuNR-HSAPs with overall average particle size of 299 ± 6 nm. Loading of
paclitaxel into PAC-AuNR-HSAPs reached 3μg PAC/mg HSA. PAC-AuNR-HSAPs
experienced photothermal heating of 46 ˚C after 15 minutes of NIR laser exposure; the
temperature necessary to cause severe cellular hyperthermia. There was a burst release of
paclitaxel up to 188 ng caused by the irradiation session, followed by a temporal drug release.
AuNR-HSAPs were tested for ablation of renal cell carcinoma using NIR irradiation in
vitro. Particles created with the same amount of AuNRs, but varying HSA (1, 5 or 20 mg)
showed overall particle size diameters 409 ± 224, 294 ± 83 and 167 ± 4 nm, respectively.
Increasing HSAPs causes more toxicity under non-irradiated treatment conditions: AuNR-
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HSAPs with 20 mg versus 5 mg HSA caused cell viability of 64.5% versus 87%, respectively.
All AuNR-HSAPs batches experienced photothermal heating above 42 ˚C. Coumarin-6, was
used to visualize the cellular uptake of AuNR-HSAPs via fluorescence microscopy.
Finally, camptothecin (CPT) an antineoplastic agent and BACPT (7-butyl-10aminocamptothecin) were loaded into HSAPs to combat their aqueous insolubility. BACPTHSAPs loaded up to 5.25 micrograms BACPT/ mg of HSA. CPT encapsulation could not be
determined. BACPT-HSAPs and CPT-HSAPs showed cytotoxicity to human sarcoma cells in
vitro.

Hybrid Nanoparticles, Photothermal Therapy, Gold Nanomaterials, Drug Delivery,
Combinational Cancer Therapies, Materials, Human Serum Albumin, Colloidal Carriers.

xi

Chapter 1
Introduction
1.1 Objectives and Aims
The objective of this research project was to develop hybrid gold nanomaterial and drug-loaded
human serum albumin nanoparticles (HSAP) for custom chemotherapeutic/photothermally active
cancer therapy platforms. HSAPs offer a combination of diagnostic and treatment functionalities
which are unique to them, when considering their natural biological protein makeup. They have the
inherent ability to seek out areas of increased blood flow, such a tumor sites, and accumulate there.
This accumulation can prove diagnostically helpful when HSAPs are conjugated to a contrast agent.
Due to the accumulation of the particles at tumor sites, they have the potential for controlled release
of drugs as well as the capacity for inclusion of other therapy outlets, such as hyperthermia.
The advantages characteristic of a hybrid treatment system allow for simultaneous targeting,
detection and multimodal therapy avenues, which do not currently exist in any one clinical therapy
option. This research work was specifically designed to 1) develop and understand a preparation
method for encapsulating gold nanomaterials into HSAPs, 2) prove the near-infrared triggered
heating capabilities of the gold nanomaterials even while they were encapsulated in the protein shell,
3) simultaneously include proven chemotherapeutic drugs into the gold-HSAPs and determine the
loading efficiencies and 4) test the heating and drug delivery effects of the drug-gold-HSAPs as
compared to particle controls in vitro.

1.2 Significance
Cancer is an enormous global health problem, accounting for 1 in 8 deaths worldwide.1
The financial cost of a disease of this magnitude is also staggering, so there is a definite crucial
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need for more efficient, less invasive, and cheaper treatments that eliminate the severe symptoms
of the therapies currently available. Human serum albumin (HSA), the most abundant human
blood protein, offers natural biocompatibility and biodegradability and is capable of conjugating
drugs, metallic nanoparticles, and other organic and inorganic substances via covalent and noncovalent attachment of its many functional groups 2, 3, 4, 5. This research work focused on
encapsulating solid gold nanoparticles, hollow gold nanoshells and gold nanorods into human
serum albumin nanoparticles (HSAPs), as well as four other chemotherapeutics: paclitaxel,
camptothecin, and 7-butyl-10-aminocamptothecin (BACPT) to show that the combination and
size optimization of these hybrid particles can serve as platforms for preparing new drug
therapies. Despite the clinical success of drug loaded HSAPs, there is a current lack of multifunctional HSAP hybrids that offer combinational therapies. This particle template allows for
potential simultaneous inclusion of anti-cancer drugs, biomarkers, or other
imaging/photodynamic molecules, along with photothermally active gold nanomaterials. The
strategy also allows for subsequent external surface functionalizing to improve control of HSAP
behavior in the body.
The combined approach will permit killing of cancer cells by both hyperthermal
treatment and localized chemotherapy treatment. The combination of treatments is more likely
to eliminate all cancer cells. The simplicity in the HSAP synthesis and entrapment of the gold
materials, and the effectiveness of maintaining the HSA’s stability and ability to bind internal
and external molecules, provide a better approach in the field of photothermal therapies using
nanoparticles. This novel approach will provide significant contributions in the fields of nanoscale drug delivery and photothermal/photodynamic therapy. Since our findings could be
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utilized to further site-specific, targeted anti-cancer therapy approaches, it can potentially boost
effectiveness and reduce damage to healthy tissue.
1.3 Human Serum Albumin Nanoparticles
Human serum albumin (HSA) is a heart-shaped, globular protein made up of 585 amino
acid residues with only one central, fluorescent tryptophan.3 HSA offers natural biocompatibility
and biodegradability, as well as the capability to be surface functionalized due to its high content
of charged amino acids.2, 5, 6, Molecular HSA has a blood concentration of 7 × 10-4 M and a total
mass of approximately 120 g, making up 50% of the protein present in plasma.3, 4, 7, Each HSA
molecule makes about 15,000 passes through the circulatory system during its 28-36 day
lifespan; picking up and unloading numerous endogenous and exogenous compounds. This vital
protein is able to make its way into the central nervous system and even across the blood-brain
barrier.3, 4, 7
HSAPs have been utilized in promising controlled release studies due to enhanced
permeability and retention effects (EPR), where molecules or particles of certain sizes
accumulate at tumor sites upon stimulation of the production of blood vessels during rapid,
irregular growth.8, 9 This effect is especially true for molecules greater than 40 kDa, which are
more readily trapped. Malignant tumors induce and increase angiogenesis and consequently,
hypervascularization. Rapid blood vessel growth in tumors causes an irregular structure with
pore sizes of 200-600 nm, thus allowing particles of ~200 nm to easily be taken into the tumor
site.9, 10 Once particles enter the tumor, there is not sufficient lymphatic drainage to remove
them; thus longer retention of carrier systems such as liposomes and albumin particles is
accomplished. 10, 11, 12, 13 Because of the natural tendency for blood accumulation at tumor sites,
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a prominent blood protein like HSA is a strong candidate for this type of EPR substantiated
cancer treatment vehicle.
The primary protein structure of molecular HSA allows for conjugating drugs, metallic
nanoparticles and other organic and inorganic substances via covalent attachment of its
functional groups, such as amine and carboxylic acid groups.2 The creation of HSAPs as a
colloidal drug carrier system multiplies this ability and allows for transport of toxic or low
solubility drugs with high loading efficiency (better than liposomes), good storage competence,
and minor leakage.11,14
Chemotherapeutic drugs have severe symptoms associated with them including drug
resistance and myelosuppression, where bone marrow activity is decreased, resulting in fewer
red blood cells, white blood cells, and platelets; so a contained transport method that delivers
drug only to the site of disease is desired.15, 16 HSA’s natural biocompatibility makes it capable
of conjugating drugs and hiding them, thus changing their pharmacokinetic profiles for stealth
drug delivery.3, 17 HSAPs have already been proven as safe medical transporters by the clinical
formulations of AlbunexTM, an echocardiographic contrast agent made of sonicated, air-filled
HSA microspheres and AbraxaneTM, paclitaxel filled HSAPs for the treatment of lung, ovarian,
breast, head, and neck cancer. 11, 15
1.3.1 Synthesis of HSAPs
Desolvation is a simple, thermodynamically driven self-assembly process for polymeric
materials by the addition of a desolvating, or denaturing, agent which coacervates the
polypeptide molecules in the aqueous phase, thus facilitating electrostatic and hydrophobic
interactions.14, 18 Because of this dependence on the attractive and repulsive forces, the pH of the
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HSA aqueous solution prior to the addition of ethanol plays a pivotal role in the ultimate size of
the formed particles, and the later influences cancer extracellular matrix interactions.14,19
Glutaraldehyde is used as a cross-linking reagent to covalently bond two amine groups.
The glutaraldehyde is needed to strengthen the HSA acervates into place after denaturation and
aggregation. The HSA amines of the 59 lysine residues and 23 arginine moieties in guanidino
side chains are crosslinked by a condensation reaction with the aldehyde groups of
glutaraldehyde.20 It has been calculated that the lowest required amount of glutaraldehyde
needed to quantitatively crosslink all 59 ε-amino groups present in 100 mg of HSA is
approximately 4.7 × 10-5 moles of glutaraldehyde (58.8 μL of 8% by volume glutaraldehyde in
H2O).20
1.5 Photothermal Therapy and Cell Hyperthermia
Plasmonic photothermal therapy (PPTT) is the phenomena whereby a metal’s surface
electrons interact with a frequency of light that matches the resonant frequency of the electrons.
Oscillations of the surface electrons, called plasmons, move in harmony with the wave resulting
in absorption.21 Through a photothermal conversion, the absorbed light is transferred to heat
energy. The therapeutic capability occurs if the wavelength of the radiation is in the biologically
safe water window (700-900 nm); with near infrared light being able to penetrate tissue in vivo at
a tumor site up to 10 cm below the skin, without affecting surrounding healthy cells. 21, 22, 23 This
particular phenomenon of heating gold nanomaterials has previously been successfully proven
safe for in vivo applications. 21, 24, 25
Moderate cell hyperthermia occurs at 43˚C and can cause increases in endocytosis and
blood flow, resulting in not only an increase in uptake of drugs, but a break down intracellular
structure 26. Increasing the induced temperature to over 46˚C will cause severe hyperthermia and
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eventual cell death through heat ablation. 27 This type of induced heat therapy shows immediate
anticancer effects, however the full benefits are hindered due to the distribution of energy within
the beam and the gradual reduction of heat in the tissues farther from the AuNR. 28 Therefore,
developing a hybrid mechanism which would also carry a proven chemotherapeutic drug along
with the AuNRs, with relatively long-lasting effects, was in order.
1.6 Gold Nanoparticles, Nanoshells and Nanorods
There has also been an emergence of new synthesis routes to manipulate gold into
nanomaterials of various shapes and sizes for therapeutics and other applications. 29, 30, 31, 32 Gold
nanorods (AuNRs), nanoparticles (AuNPs), and nanoshells (AuNSs) have the ability to absorb
and/or elastically scatter light, depending on the gold’s shape and size. The scattering ability
makes them remarkable contrast imaging agents in vivo and the absorption of photons with
matching frequencies causes the subsequent release of energy via heat, which can be harnessed
for use in plasmonic photothermal therapy.33, 34, 35, 36 Nano-sized gold’s unique absorption
properties are due to surface plasmon resonance, with the resonant frequency varying with the
shape, size, and environment of the gold particle. 21
AuNPs are inert with bio-conjugation ability, especially with thiolated molecules,
fluorophores and blood proteins like HSA. Since these particles are usually small (2-80 nm), they
are perfect for endocytosis (25-80 nm caveolae mediated uptake and up to 100 nm clatherin
mediated uptake). When the particles are encapsulated within a larger matrix, like an HSAP,
phagocytosis is a more common uptake mechanism.31, 37, 38, 39, 40
In particular, AuNRs absorption maxima can span a wide range of wavelengths due to the
fact that the particles have two distinct plasmon bands created by the transverse (short) axis and
the longitudinal (long) axis. Longer rods usually yield larger plasmon frequencies.32 Also,
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unlike spherical gold nanoparticles which are more likely to quench fluorescence via
fluorescence resonance energy transfer (FRET), AuNRs can enhance quantum yields of
fluorescent molecules at certain distances.30 This could be very useful for imaging if a
fluorophore is maximally loaded into the HSAP shell surrounding the gold nanorod.
PEGylated gold nanorods have shown to be the least toxic type of gold nanoparticle both in
vitro and in vivo and have ideal photothermally active traits. However, one study found that they
have a down side: they are rapidly excreted from the body and usually have a half-life of
approximately 1 hour. 41 Therefore, for in vivo efficiency, the composite particle size range of
100-500 nm is still ideal.42 During the rapid development of new, irregular blood vessels,
normal vascular structures are impeded, thus resulting in openings in the capillaries from 200 to
2000 nm, which allow larger particles in. 43 From there, lymphatic drainage of interstitial fluids
in the tumor site is abnormal; causing smaller particles to freely move back into circulation,
while larger particles are maintained in the tumor. 44 Therefore, it would be beneficial to
encapsulate rod-shaped gold particles into spherical HSAPs to increase overall size and loading
capabilities. The majority of this work focuses on the encapsulation of gold nanorods into
HSAPs.
1.7 CPT and BACPT
Natural products are successful sources of antineoplastic agents, accounting for greater
than 60% of the anticancer pharmaceuticals in use. 45 Camptothecin (CPT), an alkaloid isolated
from Camptotheca acuminata (the “happy tree” in China) was first isolated and reported in
1966.46, 47 Camptothecin is greatly used on primary and metastatic colon carcinoma, platinumrefractory ovarian cancer, and small cell lung carcinoma. It acts by poisoning the DNA target
enzyme topoisomerase I (top I) during its catalytic cycle of DNA relaxation, leading to the
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generation of DNA double-strand breaks and cell death by apoptosis.46,48,49,50 The problem
associated with camptothecin is that it possesses extremely low aqueous solubility; consequently
it failed in initial clinical trials conducted in the 1970s.
To reduce side effects and enhance potency, water soluble analogues of camptothecins,
namely topotecan (TPT) and irinotecan (CPT-11), were created and are increasingly in clinical
use for colorectal, ovarian and lung cancers. Despite their success, major side effects are caused
by the water-solubilizing functionalities, such as severe to life-threatening diarrhea and
myelosuppression (where bone marrow activity is decreased, resulting in fewer red blood cells,
white blood cells, and platelets).,15,16, 51 Because of this, these camptothecin derivatives are doselimiting. 52
Other methods have been explored to keep the camptothecins in their most effective state
such as: encapsulating them within dendrimers (large, branched molecules), delivering them in
conjunction with surfactants and linking them to large water-soluble polymers (e.g.,
PEGylation).52,53 In most cases, there are still side effects and reduced anticancer efficacy.
Hiding the highly effective CPT (or BACPT) in a biocompatible protein shield will accomplish
the task of maximizing efficiency while minimizing harmful effects.
BACPT, 7-butyl-10-aminocamptothecin, was developed in an effort to improve potency
and cross-resistance profiles in connection with the stability of the cleavage complex created
when bound to the over expressed top I and DNA.54 BACPT is promising because it has been
found that substitutions at the C-10 position on the molecule can increase lipophilicity, while
substitutions at the C-7 position enhances potency in vitro. BACPT is of particular interest
because it exhibits increased activity at the acidic extracellular pH environment, which is
common to many solid tumors.54,55

Large metastatic solid tumors usually have hypoxic
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environments, which promote expression of stress response genes, tumor angiogenesis and drug
resistance.

55,56,57

The cancer cell’s increased pHi (internal pH) causes cancer to spread by

avoiding apoptosis, metabolic adaptation and directed cell migration.

The decreased pHe

(extracellular pH) limits buffering, changes the extracellular matrix and enables tumor cell
invasion.
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Drug pKa has the ability to affect many biological processes: solubility, dissolution

rate, reaction kinetics, formulation, cell permeability, tissue distribution, renal elimination,
metabolism, protein binding and receptor interactions.58
1.8 Paclitaxel
Paclitaxel (PAC) is also a natural chemotherapeutic, isolated from the bark of the western
yew tree. PAC has been established as having major effectiveness in the treatment of metastatic
breast cancer, however it is also dose limited because it has low water solubility and can cause
neurotoxicity and myelosuppression, amongst other complications. 59, 60, 61 The mechanism of
PAC toxicity involves disruption of the microtubule system and blocking of cells in the late G2
and M phases of the cell cycle. 62
PAC has poorly water solubility and a broad tissue distribution profile, so it is normally
delivered in Cremophor EL (a derivative of castor oil), ethanol and saline; a formulation which
also carries toxicity. 62 With the FDA approval of Abraxane®, an HSAP with paclitaxel inside,
the paclitaxel can be used at the most antitumor efficient doses without introducing further
toxicity to the patient. 60, 63 Our hybrid particles seek to draw on the success of Abraxane with
the addition of other treatment functionalities.
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1.8 Renal Cell Carcinoma
Renal cell carcinoma was as one of the most common malignancies in Europe and the
U.S. as of 2008 and continues to make the list of most common cancers throughout the world. 1,
64

There is a worldwide annual increase in incidence of about 2%, with an estimated 63,000 new

cases predicted for the United States alone. 1, 64 The incidence of renal cell carcinoma (RCC) is
usually asymptomatic and is mostly diagnosed during imaging examinations which are usually
being performed for unrelated reasons. 65
Surgery, where the diseased portion of the kidney is removed, has traditionally been the
only curative therapeutic approach for renal cell carcinoma, with a focus on nephron-sparing
techniques, if possible. 64 Deterioration in health, tumor size, age and tumor location do not
always allow for the best surgical outcome. Therefore, other treatment approaches have been
developed to allow for minimum invasiveness. Treatment alternatives for RCC include
percutaneous radiofrequency ablation (RFA), cryoablation, microwave ablation, laser ablation,
and high intensity focused ultrasound ablation. 64 Potential advantages of these techniques
include increased quality of life, the ability to treat high-risk surgical candidates and reduced
complications caused by surgery. 64 Repeat ablation is necessary more frequently following
RFA and local progression rates for cryotherapy and RFA are poorer than rates for surgical
procedures. 64 However, if a treatment option possessed both the ability to ablate the RCC with
more heating control and also contained a mechanism for temporal, controlled release of a
proven RCC anticancer drug, such as sorafenib, the hybrid treatment could potentially eliminate
the need for repeated ablation and allow for the non-surgical treatment of tumors larger than ~3
cm.
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Overall, the dual chemotherapeutic and heating therapies supplied by the hybrid
nanoparticles described within this research are customizable and allow for: future drug
combinations, controllable heating for direct ablation and increased induced drug uptake and
contrasting and targeting amalgamations not previously seen in current clinical applications.
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Chapter 2
Encapsulating Gold Nanomaterials into Size-Controlled Human Serum
Albumin Nanoparticles for Cancer Therapy Platforms

2.1 Abstract
Progress has been made in using human serum albumin nanoparticles (HSAPs) as
promising colloidal carrier systems for the early detection and targeted treatment of cancer and
other diseases. Despite this success, there is a current lack of multi-functional HSAP hybrids
that offer combinational therapies. The size of the HSAPs has crucial importance on drug
loading and in vivo performance and has previously been controlled via manipulation of pH and
crosslinking parameters. Gold nanomaterials have also gained attention for medicinal use due to
their ability to absorb near-infrared light, thus offering photothermal capabilities. In this study,
the desolvation and crosslinking approach was employed to encapsulate gold nanorods,
nanoparticles, and nanoshells into HSAPs. Incorporation of gold nanomaterials caused some
changes in HSAP sizes, but the general size trends remained. This encasement strategy
facilitated size-controlled HSAPs, in the range of 100-300 nm, loaded with gold nanostructures;
providing composite particles which incorporate photothermally active components.
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2.2 Introduction
Some previous studies have focused on binding very small gold nanoparticles with HSA
molecules, surface functionalizing a protein corona monolayer (dynamic surface layer) of HSA
onto gold nanomaterials, and self-assembly of gold into AuNPs using HSA as the driving
medium. 29, 37, 66, 67, 68 In the body a corona layer of proteins form on a nanoparticle surface
when they are in contact with human biological proteins. These layers determine interactions
with living systems and are responsible for cellular responses to the nanoparticles. Coronas are
composed of an inner layer (hard corona) and outer layer (soft corona).69 The inner layer is
selected proteins with a lifetime of several hours.70 These manifest a slow exchange with the
environment around them. The outer layer consists of weakly bound proteins and has a faster
exchange with the environment.66,71 More biological impact comes from hard corona and their
specificity and orientation for a receptor than from the soft corona, which are replaced quickly.66,
72

Some studies on particles designed for intravenous use show there can be a suppressed

immune responses because of these interactions.73 There has also been a variety of work on
surface modifying drug-loaded HSAPs with other molecules such as biomarkers, fluorophores,
and antibodies; however, the creation of an optimally-sized gold-HSAP functional hybrid is
lacking. 8, 74, 75
This research focuses on encapsulating the nano-sized gold described above into a shell of
HSAP big enough to bind and hold an extremely high, maximum payload of drug, while
succumbing to the enhanced permeability and retention effects that will cause it to be trapped in
a cancerous matrix. Also, the HSAPs should not induce such a detrimental corona response by
biological proteins because it is seen by the body as commonplace as opposed to other capping
agents that are put onto gold nanoparticles. Capping agents, such as CTAB
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(cetyltrimethylammonium bromide), are becoming increasingly prevalent in nanoparticle
synthesis and are primarily used to stabilize the highly reactive nanoparticle surfaces to
aggregation and dissolution.76 Encapsulating otherwise unmodified gold nanomaterials in
albumin will alleviate problems associated with the toxicity of capping ligands.
The novelty of this research is in successfully combining two proven treatment
approaches: photothermally active gold nanomaterials with HSAP transporters of controllable
size. This research supplies promising template hybrids that could prove useful for future
simultaneous, custom drug-loading and photothermal therapy. We have created Au-HSAP
hybrid composites with overall diameters of 125-300 nm as a proof of concept model that has a
conceivable future as flexible, multimodal platforms for the detection and selective treatment of
cancer and other diseases. 32, 77, 78, 79
2.3 Experimental Methods
2.3.1 Materials and Reagents
Human serum albumin, lyophilized powder ≥ 97%, potassium bromide, and 8% aqueous
glutaraldehyde were obtained from Sigma Aldrich (St. Louis, MO). Ethanol, 200-proof,
ACS/USP grade was obtained from Pharmco-AAPER (CT, USA). Two types of spherical gold
nanoparticles were prepared at the University of California, Santa Cruz: Approximately 28 nm
diameter solid (still slightly porous) gold nanoparticles (2.4 × 1012 AuNPs/mL in water) and ~53
nm outer diameter hollow gold nanoshells with ~4 nm thick shells (7.9 × 1010 AuNSs/mL in
water). Both the AuNPs and AuNSs were created with a polyvinylpyrrolidone (PVP) coating that
was used to drive the formation during the galvanic replacement of cobalt nanoparticles by Au3+
ions 80. Phosphate buffer (pH 7.2) was obtained from VWR International (Radnor, PA). Water
was distilled, deionized, and then further purified with a Barnstead Nanopure system.
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Bare gold nanorods (10 nm average axial diameter, 43 nm average length, surface plasmon
resonance ~ 808-829 nm, OD = 1, 5.9 × 1011 AuNR/mL in water) were obtained from Nanopartz,
Inc. (Loveland, CO). The AuNRs used were advertised by the vendor as “bare”, but they did
contain trace amounts of cetyltrimethylammonium bromide. To prepare a solution of 1.2 × 1013
AuNR/mL, 2 mL of the original stock solution (5.9 × 1011 AuNR/mL) was centrifuged at 13,000
RPM (16,060 g) for 1 hour until a pellet resulted. The pellet was dispersed in ~ 0.1 mL of water.
The process was the same for creating a AuNR solution of 1.77 × 1013 AuNRs/mL from 3 mL of
the original 5.9 × 1011 AuNR/mL gold solution.
2.3.2

Synthesis of HSAPs and Au-HSAPs
The HSAPs were prepared using a conventional desolvation technique. 6, 81, 82, 83 The

standard method for preparation included the addition of 20 mg of solid HSA to 1 mL of water.
After dissolving, the pH was around 7. Any manipulation of pH was completed at this point by
addition of 0.1 M NaOH (aq.). A small stir bar was added to the solution, and 3 mL of 100%
ethanol was added at a rate of 1 mL/min using a peristaltic pump. Upon addition of the ethanol,
the solution became turbid. Finally, 4.7 μL of 8% glutaraldehyde (aq.) was added to crosslink
the HSA within the particles. After 24 h of stirring, the particles were centrifuged at 13,000
rpm (16,060 g) for 30 minutes to 1 hour. The supernatant was removed and the remaining
pellet was resuspended and washed twice with water. The particles were stored at 4 °C. In
order to encapsulate gold nano-materials into the HSAPs, various amounts of gold
nanomaterials were added to the aqueous albumin solution prior to addition of ethanol.
The synthesis was also done in a scaled-down manner whereby the mass of HSA,
volume of water, volume of ethanol, and amount of glutaraldehyde used were all reduced by
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one-fourth to create smaller batches of HSAPs. Parameters used for preparing HSAPs with and
without gold are provided in Table 2.1.
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Table 2.1. Preparation Parameters used to create HSAPs with and without gold nanomaterials.

a
c

Sample

HSA
(mg)

Water
(mL)

pH

EtOH
(mL)
3
3
3
3
3

Aq. gold
nanomaterial
solution (mL)
None
None
None
None
None

Theoretical
Gold:HSA particle
number ratioa
0
0
0
0
0

HSAP-1
HSAP-2
HSAP-3
HSAP-4
HSAP-5

20
20
20
20
20

1
1
1
1
1

7
8
9
7
9

HSAP-6

5

0.25

7

0.75

None

0

AuNR-HSAP-1
AuNR-HSAP-2
AuNR-HSAP-3
AuNR-HSAP-4
AuNR-HSAP-5
AuNP-HSAP-1
AuNP-HSAP-2
AuNP-HSAP-3

5
6
2
2
5
5
5
2.5

0
0
0
0
0
0.25
0.25
0.125

7
7
7
7
7
7
7
7

3
1.5
5
1.5
3
1.5
2.25
3

1.0 AuNRb
0.5 AuNRb
2 AuNRb
0.1 AuNRc
0.1 AuNRd
0.25 AuNPe
0.5 AuNPe
0.75 AuNPe

1:1.5
1:3.7
3.2:1
3.2:1
1.9:1
1:1.5
1.3:1
3.9:1

AuNP-HSAP-4

2

0.1

7

3

0.9 AuNPe

5.9:1

AuNP-HSAP-5
AuNP-HSAP-6
AuNS-HSAP-1
AuNS-HSAP-2
AuNS-HSAP-3

0.5
5
5
5
2.5

0.025
0
0.25
0.25
0.125

7
7
7
7
7

3
3
1.5
3.75
3

0.95 AuNPe
1.0 AuNPe
0.25 AuNSf
1.0 AuNSf
0.75 AuNSf

25:1
2.6:1
1:46
1:12
1:7.7

AuNS-HSAP-4

2

0.1

7

3

0.9 AuNSf

1:5.1

AuNS-HSAP-5

0.5

0.025

7

3

0.95 AuNSf

1:1.2

3 b
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Based on all HSA forming 200 nm diameter spherical particles with d = 1.3 g/cm ; 5.9 × 10 AuNR/mL;
1.18 × 1013 AuNR/mL; d1.77 × 1013 AuNR/mL; e2.4 × 1012 AuNP/mL; f7.9 × 1010 AuNS/mL
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Glutaraldehyde (μL
of 8% aqueous
solution)
4.7
4.7
4.7
9.4
9.4
9.4 (2%
glutaraldehyde)
2.4
2.4
2.4
2.4
2.4
2.4
4.8
2.4
2.4 (2%
glutaraldehyde)
2.4
2.4
2.4
4.8
2.4
2.4 (2%
glutaraldehyde)
2.4

2.3.3

Density Separation
A potassium bromide solution was prepared by mixing ~75 g KBr with water (total

solution volume was 100 mL) and stirring at 100°C for 4 hours. The density was calculated to
be ~1.45 g/cm3. AuNR-HSAPs were prepared via their respective parameters (Table 2.1) and
centrifuged at 13,000 rpm for 1 hour to create a pellet. After removing the aqueous
supernatant, 1 mL of the KBr solution was added to the pellet and the sample was
homogenized by sonication for 10 seconds. The particles resuspended in the aqueous KBr
were then centrifuged at 13,000 rpm for 30 minutes to one hour. The supernatant (containing
any particles with a density of ~1.45 g/cm3or less) was removed from the red precipitate.
Particles in the supernatant were washed several times by centrifugation with pure water. The
remaining red pellet from the KBr centrifugation was also washed several times with water.
2.3.4

Absorbance
Absorbance measurements of the HSAPs and AuNS/NP/NR-HSAPs were performed

with a Cary 60 absorbance spectrometer (Agilent Technologies).
2.3.5

Dynamic Light Scattering

The completed HSAPs were characterized by measuring the diameter and zeta potential
using a Mobius dynamic light scattering (DLS) instrument (Wyatt Technology Corporation,
Santa Barbara, CA). Samples were diluted with water prior to analysis.
2.3.6 SEM and TEM
Particles were imaged using a field emission-scanning electron microscope FESEM, LEO
1530VP (LEO Elektronenmikroskopie GmbH, Oberkochen, Germany). HSAPs were sputtered
with a thin film of gold or silver to facilitate imaging. Transmission electron microscope (TEM)
images were acquired with a JEOL Model 2010 TEM or with cryo-TEM using an FEI G2 F30
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Tecnai TEM (FEI, Hillsboro, OR) with a Gatan-626 cryo-specimen holder and cryotransfer
system (Gatan, Warrendale, PA).
2.4

Results and Discussion

2.4.1 HSAP Formation
Desolvation is a simple, thermodynamically driven self-assembly process for polymeric
materials by the addition of a denaturing agent, which coacervates the polypeptide molecules in
the aqueous phase, thus facilitating electrostatic and hydrophobic interactions. 14,18 Because of
this dependence on the attractive and repulsive forces, the pH of the HSA aqueous solution, as
well as the amount of cross-linker added, play pivotal roles in the ultimate size of the formed
particles. Particle size also influences interactions of the particles with the cancer extracellular
matrix. 14,19 Experiments were done to confirm preparation parameters, which have been
previously well documented, that would yield 150-300 nm diameter unloaded HSAPs and to
compare the preparation-based sizing trends to size outcomes of the gold-loaded HSAPs. Figure
2.1 shows an FESEM image of HSAPs with no gold or drug loaded inside.

Figure 2.1. FESEM image of 200-300 nm diameter HSA particles.
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Experiments were done to find a starting pH that would yield 150-300 nm diameter HSAPs
by adjusting the pH from ~6.8 – 10. Because the isoelectric point (pI) of HSA is ~4.7 to 5.4, it is
not fruitful to try to form particles under pH 6. HSA has a zero net charge at these pH values,
which causes unwanted, excessive aggregation of the particles and erratic size outcomes.
Table 2.2. Averaged DLS data for HSAPs
Sample

Initial
pH

Theoretical
Diameter
Polydispersity (%) ζ (mV)
%
(nm)
Crosslinked
HSAP-1
7
40
248 ± 66
14
-14
HSAP-2
8
40
151 ± 23
8
-27
HSAP-3
9
40
140 ± 29
21
-28
Error represents one standard deviation with N ≥ 3. All reported diameters were statistically
different at 95% confidence.
Consistent with other literature reports, as the pH of the starting solution of HSA/water
is increased, final HSAP size decreases, as seen in Table 2.2 and Figure 2.2. Note that Figure
2.2 takes into consideration only those samples created with 20 mg HSA (see Table 2.1). The
size decrease from ~248 ± 66 nm (at pH 7) to ~151± 23 nm (at pH 8) to ~140 ± 29 nm (at pH
9) is likely due to an increase in net charge of the HSA molecules, which leads to the repulsion
of HSA molecules and less aggregate formation. 20, 81, 83
At higher pH levels, the HSA became more negatively charged due to greater
dissociation of protons at high pH, so smaller HSAPs were formed. The electrophoretic
mobility (μE), the migration velocity per unit electric field) and the zeta potential (ζ, the
electrokinetic potential of a molecule on its outer layer, slipping plane or diffuse layer), give
insight into the charge and stability of the HSAPs as a colloid.84 The larger the zeta potential
value is (either positive or negative), the more stable the colloidal system. As a rule of thumb,
HSAPs are generally very stable as colloids at ζ > +25 mV or ζ < -25 mV, therefore it seems
that the HSAP-2 (pH8) and HSAP-3 (pH9) particles with zeta potentials of -27mV and -28mV,
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respectively, are more stable that the HSAP-1 (pH7) particles that have a zeta potential of 14.84
This desolvation process has the potential to theoretically make trillions of particles
based on the average size of the particles created and the amount of milligrams of HSA used in
the batch. For example (assuming the density of the HSAP remains that of molecular HSA at
1.31 g/cm3 and the average particle size created is 200 nm): taking into consideration the
volume of the sphere, the mass per HSAP would be 5.48 × 10-12 mg. If 20 mg of HSA powder
was used (and all of it goes into making HSAPs), then 3.65 × 1012 HSAPs would be produced.
It should be taken into consideration however, that when any preparation parameter is changed,
such as starting pH, crosslinking level or mg HSA used, the number of particles created will be
affected due to the change in size outcome. Also, a gold particle is present inside of an HSAP,
it takes up space and volume, leaving HSA that would normally fill that space free to make
even more HSAPs. Therefore, it is possible that when gold is present, even more HSAPs are
created.

Figure 2.2. Effect of initial pH on HSAP size with 20 mg HSA and 40% theoretical crosslinking
(black bars) and 80% theoretical crosslinking (white bars). Data are from HSAP-1, HSAP-2,
HSAP-3, HSAP-4, and HSAP-5. Error bars represent one standard deviation with N ≥ 3.
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After ethanol is used to denature HSA, resulting in the formation of spherical HSAPs,
glutaraldehyde is used as a cross-linking reagent to covalently crosslink the HSA acervates into
place after aggregation. The amine groups of the 59 lysine residues, and the 23 arginine moieties
in guanidino side chains on the HSA, are crosslinked by a condensation reaction with the
aldehyde groups of glutaraldehyde. 20 It has been calculated that the lowest required amount of
glutaraldehyde needed to quantitatively crosslink all 59 ε-amino groups present in 100 mg of
HSA is approximately 58.8 μL of 8% (V/V) glutaraldehyde in H2O. 20 All theoretical
crosslinking calculations were based on this previous work and it has been customary for groups
working with this desolvation and crosslinking process to use percentage values to indicate
crosslinking; even though it is essentially impossible to crosslink over 100% of the amino groups
present on the HSA. 20, 85 Tables 2.2-2.5 list crosslinking percentages over 100%. This means
that glutaraldehyde was added in excess as compared to the necessary theoretical amount to link
all HSA amines to each other with a molecular glutaraldehyde linker.
Previous studies have found that an increase in the glutaraldehyde crosslinker used
leads to more stable HSAPs 11, 13. That increase in stability leads to particles that are not as
easily digested or broken apart. Even though there is no difference in cellular uptake with a
change in crosslinking, a high degree of crosslinking is not ideal for easy release of the
therapeutic elements inside.11, 13 We have found that there was a decrease in average diameter
from 140 ± 29 nm to 96 ± 11 nm for particles created at pH 9 when the mole ratio of
glutaraldehyde:HSA was doubled from ~12.7 to 25.4 (hallow bars in Figure 2.2). The zeta
potential showed increases from -14, -27 and -28 mV (for HSAP-1, HSAP-2, and HSAP-3,
respectively) to -35 and -30 mV (for HSAP-4 and HSAP-5, respectively) when the amount of
crosslinking agent was increased.
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2.4.2

HSAP Formation: Reagent HSA Effects

The above mentioned preparation effects on size trends are well documented, however
there was one interesting experimental outcome that had not previously been found in the
literature: the effects of the starting mass of HSA on the size outcome. In an effort to minimize
consumption of starting materials, the amount of each reagent was cut by one-fourth: 5 mg of
HSA was dissolved into 0.25 mL of water and 0.75 mL of ethanol was delivered, followed by
2.36 μL of 8% aqueous glutaraldehyde (1.9 × 10-6 moles). It was noticed that decreasing the
amount of reagents used caused a change in HSAP size and zeta potential. Despite preservation
of mole ratios, there was an unexpected decrease in observed HSAP size with smaller batches
(compare HSAP-6 to HSAP-4 in Table 2.2). At 80% theoretical crosslinking, the average
diameter of HSAPs created at pH 7 in the original 20 mg HSA batch was 220 ± 25 nm, but the
average diameter of the same type of particles created in a 5 mg batch was 135 ± 3 nm.
Since the starting mass of HSA had an effect on the size of the resulting nanoparticles,
careful attention must be paid to parameters during scale-up for manufacturing purposes or even
for preclinical and/or clinical research85. This size effect may be due to changes in the number of
nucleation sites.
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Table 2.3. Particle size and zeta potential data for AuNR-HSAPs.
Sample

Theoretical % Crosslinked

Diameter (nm)

Zeta Potential (mV)

AuNR-HSAP-1

80

222 ± 5a

-20

AuNR-HSAP-2

80

262 ± 20

-13

AuNR-HSAP-3

200

190 ± 1

-19

AuNR-HSAP-4

200

119 ± 4

-91

AuNR-HSAP-5

80

152 ± 20

-23

a

Error represents one standard deviation with N ≥ 3. All reported diameters were statistically
different at 95% confidence.

2.4.3

Formation of Composite Au-HSA Particles

The aim of this project was to create Au-HSA composite particles for potential future use
in photothermal therapy. We utilized three separate types of gold nanomaterials: rods, spheres
and shells. Empty HSAPs created with 5 mg of HSA in 0.25 mL of H2O with addition of 0.75
mL of EtOH and crosslinked with 9.4 μL of 2% glutaraldehyde yielded samples with a size of
135 ± 3 nm, therefore it was assumed that the AuNS-HSAPs and AuNP-HSAPs created under
similar desolvation parameters would yield roughly the same particle size. That hypothesis
proved correct. The protocol followed that of forming unloaded HSAPs (Section 2.4.1)
however, Au nanomaterials were dispersed in aqueous albumin solutions prior to coacervation
of the albumin. Because gold is readily coordinated by amines and other functional groups in
the albumin, we expected the albumin to coat the surface of the gold prior to coacervation,
resulting in the gold particles acting as nuclei for coacervation. We utilized several approaches
to prove that the Au and HSA particles were in fact associated.
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The ratio of gold particles to albumin particles was calculated for each preparation (see
Table 2.1). For example, using the AuNR-HSAP-1 preparation method, if all 5 mg of HSA
formed spherical particles with an average size of 200 nm, then the process was capable of
creating 9.13 ×1011 HSAPs (assuming the HSAPs have a density equal to that of molecular
HSA, 1.31 g/cm3). Adding 1 mL of AuNR solution to the HSA would yield a AuNR:HSAP
ratio of ~ 1:1.5. This means ~ 66% of the particles would be loaded with a gold nanorod if
encapsulation were perfect.
Extensive analysis of multiple Au-HSAP samples by TEM and cryo-TEM revealed only
Au-HSAP and unloaded HSAP particles; free gold particles were observed only in rare cases.
(Representative figures for AuNR-HSAPs, AuNP-HSAPs and AuNS-HSAPs are shown later in
this chapter.) In every case where both Au and HSA particles were co-located, the Au was
fully within the outer boundary of the HSA particle; completely encapsulated into the HSA.
It is worth noting that the sample preparation is different for cryo-TEM and conventional
TEM imaging. In the case of cryo-TEM, the samples are freeze dried; thus the cryo-TEM
samples avoided the agglomeration that was apparent for the conventional TEM observations.
In addition, heating from the intense electron beam in the conventional TEM likely cause some
melding (aggregation) of the Au-HSAPs, since the proteins are highly affected by the heat.
Such issues were avoided in cryo-TEM by cooling the sample during imaging.
2.4.4

Formation of Composite AuNR-HSA Particles

AuNR-HSAPs were formed using the preparation parameters in Table 2.1. In order to
confirm that the AuNRs and HSA were actually encapsulated, we performed a centrifugal
separation using a 1.45 g/cm3 liquid medium (concentrated aqueous KBr). This separation
resulted in two types of red materials: 1) material that precipitated (d > 1.45 g/cm3) and 2)
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material that remain suspended (d < 1.45 g/cm3). The red color of these materials was due to
gold. Unloaded HSAPs are white or faint yellow in color, but never red. Free gold, with a
density of 19.3 g/cm3, would have precipitated completely in this system. The suspended red
material contained gold and had a density of less than 1.45 g/cm3. The only explanation for
this result is that the gold was encapsulated into an albumin particle with low density, so that
the average density of the composite particle was less than 1.45 g/cm3. For a 200 nm diameter
spherical HSAP with a single 10 nm diameter × 43 nm long gold nanorod, the density would
be ~1.32 g/cm3. These composites would therefore remain suspended in the KBr solution upon
centrifugation.
We visualized the supernatant and the red precipitate from this centrifugal separation using
TEM. Images of what was found in the supernatant are presented later in Figures 2.7a thru e.
Although some unloaded-HSAPs were observed by TEM in the supernatant, numerous
particles with nanomaterials inside them were observed. These observations are consistent
with the conclusion that the gold was loaded into albumin particles. The precipitate consisted
of aggregated HSAPs with multiple gold nanoparticles loaded inside of them (see Figures 2.3
a. and b.).
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Figure 2.3. TEM images of AuNR precipitate layer after density separation for (a) AuNRHSAP-1 (Inset: the image is further magnified) and (b) AuNR-HSAP-5.

Because of the high gold loading, these particles had a large density and were precipitated
in the centrifugation. No free gold nanoparticles were observed in the precipitate, suggesting
that gold particles served as nuclei for albumin coacervation. This conclusion is reasonable
since free albumin is known to bind strongly to gold. 71 Further evidence that the gold was
encapsulated in the albumin was provided by absorbance measurements. We collected the
absorbance spectrum of the supernatant from the centrifugal separation and compared this
spectrum to that of free AuNRs in aqueous solution. The spectra are presented in Figure 2.4.
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Figure 2.4. Absorbance of AuNR-HSAP-3 loaded particles (solid line) and a stock solution of
free AuNRs with a concentration of 8.31 × 1010 AuNRs/mL (dashed line).

The AuNR-HSAP spectrum was background subtracted to eliminate absorbance and
scattering signals from the HSAP, and considerable noise is present. Nevertheless, signals for
both the transverse and longitudinal Au localized surface plasmon resonances (LSPR) are
clearly visible near 540 and 850 nm. These peaks are shifted considerably from the peaks for
free AuNR (520 nm for transverse axis LSPR and 800 for longitudinal LSPR). Such shifts are
expected when the surface of the gold has strong interactions with other materials. 30, 66
Because of the large shifts in the LSPR and the high likelihood of concurrent changes in
absorptivity, we did not perform quantitative measurements by absorbance to determine the
amount of gold trapped in these particles.
A final test to prove association of the gold with the HSAPs involved measurement of
particle size and zeta potential. We compared these parameters for free AuNRs, AuNR-HSAPs
(as collected from the KBr supernatant) and unloaded HSAPs. The observed hydrodynamic
diameters for these samples were 57 ± 7 nm, 219 ± 13 nm, and 220 ± 25 nm, respectively. The
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AuNR-HSAP showed a particle size distribution similar to that of unloaded HSAP, and the
AuNR-HSAP sample had no evidence of particles with diameters corresponding to free AuNR
(see Figure 2.5).

Figure 2.5. Particle size distributions for (a) free AuNRs, (b) gold-loaded HSAPs created
via the AuNR-HSAP-1 method, and (c) unloaded HSAPs.

Consequently, the light scattering measurements support the conclusion that the gold in the
AuNR-HSAP sample was not free. The measured zeta potential of the free AuNRs, AuNRHSAPs and the unloaded HSAPs were -4.0 ± 1, -30 ± 8 and -35 mV, respectively. The gold
loaded albumin particles and unloaded albumin particles had zeta potential values that were
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indistinguishable and much greater than free gold particles, suggesting that the gold particles
were encapsulated in the albumin.

a.

b.

Figure 2.6. : a) FESEM image of AuNR-HSANP-1 with a gold rod visible at the surface (see
arrow). Tips of other rods may also be visible (light regions on particles) and b) TEM image of
AuNR-HSANP-2 particles with a gold rod visibly surrounded by a layer of albumin

Taken together with the TEM images and the absorbance data presented above, the particle
size and zeta potential data further confirm that the gold was associated with albumin particles
and was not present as free nanorods. Additional inspection of an FESEM image in Figure 2.6a
reveals a rod apparently positioned on its axial side, protruding down into the HSAP.
Evidence of HSAP particle deformation is visible in Figure 2.6b in which the HSAP shape
conforms to the outline of the AuNR at the edge of the albumin particle. There is also
evidence of multiple rods being loaded into one HSAP (Figure 2.8a thru e); some with
nanorods apparently both parallel and perpendicular to the plane of view (Figure 2.8d and
2.8e). With a limited amount of gold nanoparticles, loading multiple gold particles into each
albumin particle further decreases the chance of each albumin particle being loaded with a gold
particle.

30

Figure 2.7. Cryo-TEM images of singly loaded AuNR-HSAPs from (a) AuNR-HSAP-1; (b and
c) AuNR-HSAP-2 and (d and e) conventional TEM images of AuNR-HSAP-3.

Figure 2.8. (a, b and c) Conventional TEM images of AuNR-HSAP-3; (d) cryo-TEM image of
AuNR-HSAP-1 (e) and cryo-TEM image of AuNR-HSAP-2. All images show particles with
multiple gold rods trapped within the HSAP.
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Table 2.3 presents the particle size and zeta potential data for the AuNR-HSAPs. The
observed diameters were between 119 ± 4 and 262 ± 20 nm and varied depending on the
preparation parameters. As the amount of HSA decreased, the particle size decreased as well.
The zeta potentials for these particles were all negative, but were slightly smaller than desired to
maintain a stable colloid without aggregation. To combat this, further ultrasonication is needed
to break up particle aggregation after the heavy centrifugation technique used in the density
separation.
It is evident that the loading ratio of AuNRs:HSAPs determined through theoretical
calculations (Table 2.1) were not represented in the ultimate formed particles. This discrepancy
is partially due to the fact that HSAPs are capable of loading multiple rods, which was
unexpected and opportune. In addition, loading a nanorod into an HSAP takes up a volume of
space and therefore, decreases the amount of molecular HSA in that particle, freeing it for the
formation of additional HSAPs. Third, the calculations were based on an average HSAP size of
200 nm, however when the average particle size decreases, many more HSAPs are formed.
The lack of gold in some of the particles did not seem to affect other characteristics of the
particles, as the morphology remained spherical (aside from any slight changes to the albumin
shape to accommodate encapsulated gold particles). The sizes remained within the expected
range, and the zeta potentials remained negative, indicating stability. The presence of the gold
did not increase aggregation of the particles. As proven via the density gradient study, free
AuNRs could not be found. Every AuNR found using microscopy was in some way associated
with an HSA coating, therefore the efficiency of gold incorporation can be said to be close to
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100%. However, the distribution was not completely uniform. Some AuNR-HSAPs were
formed with six rods encapsulated, while some HSAPs formed with no rods encapsulated.
The AuNR-HSAP-3 preparation method (containing 2 mg HSA and 2 mL AUNR stock
solution) was the most successful method in this trial, yielding the greatest extent of albumin
particles loaded with gold (see Figure 2.9). This result illustrates that adjusting the formation
parameters can control the gold loading and particle size. However, additional work is needed to
further optimize the particle characteristics.

Figure 2.9. TEM image of particles created via the AuNR-HSAP-1 method with increased
loading of AuNRs; illustrating the non-uniformity of loading. There is some melding of particles
present due to the heating from the electron beam.

2.4.5

AuNS-HSAPs and AuNP-HSAPs Formation

Unloaded, HSAPs created with 5 mg of HSA in 0.25 mL of H2O with addition of 0.75 mL of
EtOH and crosslinked with 9.4 μL of 2% glutaraldehyde (aq.) yielded samples with a size of 135
± 3 nm. Particle size measurements for composite particles revealed an average diameter of 156
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± 15 nm for AuNS-HSAP-1 and 195 ± 9 nm for AuNP-HSAP-1. These particles remained under
200 nm in average diameter, an effective size range for use as a treatment vehicle. Tables 2.4 and
2.5 show the size and zeta potential information for the AuNS and AuNP loaded HSAPs,
respectively. These particles are slightly smaller compared to an average of 245 ± 66 nm for
unloaded HSAPs.

Table 2.4. Particle size and zeta potential data for AuNS-HSAPs.
Sample

Theoretical
Diameter
Zeta
%
(nm)
Potential
Crosslinked
(mV)
AuNS-HSAP-1
80
156 ± 15a
-26
AuNS-HSAP-2
160
102 ±1
-20
AuNS-HSAP-3
40
109 ± 4
-17
AuNS-HSAP-4
50
54 ± 2*
-26
AuNS-HSAP-5
800
51 ± 1*
-18.5
a
Error represent one standard deviation with N ≥ 3. All reported diameters were
statistically different at 95% confidence except those noted by *.
Table 2.5. Particle size and zeta potential data for AuNP-HSAPs.
Sample

Theoretical
Diameter
Zeta
%
(nm)
Potential
Crosslinked
(mV)
AuNP-HSAP-1
80
195 ± 9
-25
AuNP-HSAP-2
160
109 ± 1
-35
AuNP-HSAP-3
40
122 ± 1
-16
AuNP-HSAP-4
50
86 ± 1
-27
AuNP-HSAP-5
800
67 ± 1
-17
a
Error represents one standard deviation with N ≥ 3. All reported diameters were
statistically different at 95% confidence.
Figure 2.10a presents a cryo-TEM image of hybrid particles from AuNS-HSAP-2, clearly
illustrating that the gold particles were encapsulated with albumin particles. There is also
evidence of individual AuNS-HSAPs incorporating more than one gold nanoshell. Figure 2.10b

34

presents a cryo-TEM image of AuNP-HSAP-1, where some albumin particles do not have gold
inside. The ratio of AuNP to HSAP in this batch was approximately 1:1.5, indicating that the
AuNP were present as a limiting reagent. Consequently, it is not surprising that we observed
numerous unloaded HSAPs (not depicted) and no evidence of free AuNPs.

Figure 2.10. Cryo-TEM images of (a) AuNS-HSAP-2 and (b) AuNP-HSAP-1.
Figure 2.6: Cryo-TEM images of (a) AuNS-HSAP-2 and (b) AuNP-HSAP-1.
As seen in Tables 2.4 and 2.5, the average particle size and zeta potential observed for
the various AuNP-HSAP and AuNS-HSAP preparations followed similar trends, suggesting
that the preparation parameters can be generalized to the incorporation of any type of gold
nanoparticle. For both AuNS-HSAPs and AuNP-HSAPs, increasing the extent of crosslinking
resulted in smaller particles. This result is consistent with that of unloaded HSAPs, as
previously discussed. For both AuNS and AuNP loading in Figures 2.10a and 2.10b, it is
believed that insufficient gold particles were present to achieve complete loading of the
albumin particles (due to the freeing of HSA when a gold particle takes up volume), and no
evidence of free AuNPs or AuNSs was observed after extensive TEM observation.
For the purpose of creating a particle with high drug payload capacity and large ligand
binding capabilities, the particle size distribution of AuNP-HSAP-5 (Figure 2.11) samples should
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still prove sufficient, as it still had substantial HSAP volume around the gold and high surface
area per gram due to the smaller particle size. The solid gold particles were roughly 10-30 nm,
and the resulting AuNP-HSAPs were on average 67 ± 1 nm; that is a diameter increase of ~55 to
85%, which verifies the albumin coating as substantially more than a monolayer of HSA
surrounding the gold. Thin HSA coatings (less than 15 nm thick) on gold nanoparticles have
previously been reported as corona layers. 29, 37, 67, 68 However, those particles would not have the
same drug loading capacity as those produced in this study due to the thicker coating of HSA
achieved here.

Figure 2.11. TEM image of AuNP-HSAP-5 particles created with less HSA.

2.5 Conclusions
In this study, composite AuNP-HSAPs, AuNS-HSAPs, and AuNR-HSAPs were successfully
prepared as a proof of concept to show that these composite particles can serve as platforms for
preparing new drug therapies. This research has shown that size-controlled encasement of these
gold nanomaterials into larger (100-300 nm) HSAPs is possible via a desolvation and
crosslinking process. Moreover, the same preparation parameter manipulations that allow for
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controllable particle size of medicinally useful HSAPs are in operation when the procedure is
conducted with gold nanomaterials present. One new development regarding the preparation
process for making unloaded HSAPs is that the starting mass of HSA plays a role is the size
outcome. Since the ultimate goal is effective treatment of cancer cells via targeted drug delivery
and photothermal therapy, simultaneously loading of HSAPs with both gold nanomaterials and
an appropriate drug is a future direction for these studies. The combined approach will allow
killing of cancer cells by both hyperthermia and localized chemotherapy treatment and is more
likely to eliminate all cancer cells.
In addition, the photothermal approach may serve as a trigger for drug release once the
particles have reached their targeted tissue. Functionalizing the surface of the HSAPs with
disease-specific targeting ligands may lead to even more effective delivery of cancer therapies to
the site of the disease, boosting effectiveness and reducing damage to healthy tissue. 86 The
optimal number of gold nanoparticles loaded into each HSAP to achieve effective hyperthermic
treatment is not yet known, but is the subject of ongoing studies, as is improving the control of
AuNP loading efficiency. Furthermore, the effect of radiative heating of gold nanomaterials in
HSAPs on the release of simultaneously encapsulated drugs also needs additional study.
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Chapter 3
Hybrid Gold Nanorod-Human Serum Albumin Nanoparticles for
Simultaneous Chemotherapeutic and Photothermal Therapy Platforms

3.1 Abstract
Human serum albumin nanoparticles (HSAPs) as drug carrier systems for treatment of
cancer have proven successful through current marketable clinical formulations. Despite this
success, there is a lack of multi-functional HSAP that offer combinational therapies from more
than one proven technique. Gold nanorods (AuNRs) have also shown medicinal promise due to
their photothermal therapy capabilities. In this study, the desolvation and crosslinking approach
was employed to successfully encapsulate gold nanorods into HSAPs along with incorporation of
the chemotherapeutic drug paclitaxel (PAC), forming PAC-AuNR-HSAPs with desirable overall
particle sizes of 299 ± 6 nm. The loading efficiency of paclitaxel into PAC-AuNR-HSAPs
reached up to 3μg PAC/ mg HSA. The PAC-AuNR-HSAPs experienced photothermal heating,
with bulk solution temperatures reaching up to 46 ˚C after 15 minutes of near-IR laser exposure,
indicating successful attainment of the temperature necessary to cause severe cellular
hyperthermia and necrosis.
This encasement strategy facilitated a colloidal hybrid treatment system capable of
enhanced permeability and retention effects, photothermal ablation of cancer cells, and release of
the active paclitaxel of up to 188 ng (from PAC-AuNR-HSAPs created with 30 mg HSA) in a
single 15 minute irradiation session. The system also lends itself to future customizable external
functionalities via conjugated targeting ligands such as antibodies. Internal entrapment of patient
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tailored medication combinations are also possible with this combination treatment platform,
which may result in improved quality of life for those undergoing treatment.
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3.2 Introduction
There is a current need for multi-functional, temporally active cancer treatments which
maximize therapeutic effects through less invasive techniques. A hybridization of effective
treatments can offer combinational therapy, which may result in higher success rates and
increased quality of life for patients suffering with the disease. Gold nanorods (AuNRs) have the
ability to absorb relatively harmless near infrared light, causing the subsequent release of energy
via heat, which can be harnessed for use in plasmonic photothermal therapy (PPTT). 22, 34, 35, 86
Moderate cell hyperthermia occurs at 43˚C and can cause increases in endocytosis and
blood flow, resulting in not only an increase in uptake of drugs, but a breakdown in cellular
structure.26 Increasing the induced temperature to over 46˚C will cause severe hyperthermia and
eventual cell death through heat ablation.27 This dose-controllable heat therapy shows
immediate anticancer effects; however, the full benefits are hindered due to the distribution of
power within the beam and the gradual reduction of heat in the tissues farther from the AuNR.28
Therefore, developing a hybrid mechanism to also carry a proven chemotherapeutic drug along
with the AuNRs, with long-lasting staying power is desirable.
In a previous study, we focused on a proof-of-concept synthesis to fully encapsulate gold
nanorods into HSAP spheres to harness their PPTT effects; with the goal of keeping them from
being susceptible to clearing the body as fast as smaller, drug-conjugated AuNRs prepared by
other researchers.41, 87 Human serum albumin (HSA), the most abundant human blood protein,
offers biocompatibility, biodegradability, and the ability to conjugate drugs and other organic
and inorganic substances via covalent and non-covalent attachment to its many functional
groups.17, 3 When aggregated together via a desolvation and crosslinking technique, HSA forms
nanoparticles (HSAPs).
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These HSAPs have previously been surface modified for diagnostic and targeting
functions and utilized in controlled release studies, due to enhanced permeability and retention
effects (EPR); where particles of certain sizes accumulate at tumor sites. 5, 8, 9 Our previous
approach allowed for internal binding to the HSA hydrophobic pockets as well as external
surface functionalizing of the HSAPs, even with AuNRs present. The HSAPs are largely capable
of binding a multitude of biomarkers, fluorophores, antibodies, etc. Because the HSAP are
larger than the individual gold particles, the HSAP can bind more materials than bare AuNRs
alone .74, 75, 88, 8
Paclitaxel (PAC) is a natural chemotherapeutic agent isolated from the bark of the
western yew tree. PAC has been established as having major effectiveness in the treatment of
metastatic breast cancer; however, it is dose limited because it has low water solubility and can
cause neurotoxicity and myelosuppression amongst other complications.59, 60, 61 Paclitaxel-filled
HSAPs have been proven as safe medical transporters as used in the clinical formulation
AbraxaneTM; which has been successful in the treatment of lung, ovarian, breast, head and neck
cancer.63 With the FDA approval of Abraxane®, paclitaxel can be used at the most antitumor
efficient doses without introducing further toxicity to the patient.60
In 2013, Abraxane was also approved for use in treating pancreatic cancer as a less toxic
alternative to folfirinox and it is expected to become the standard of care for pancreatic cancer.89,
90, 91

The “nab-paclitaxel” particles (nanoparticle albumin-bound) allow for transport of toxic or

low solubility drugs with high loading efficiency, good storage competence, and minor
leakage.11, 15, Our approach utilizes this up-and-coming particle formulation and improves its
treatment potential with the option of controlled heating: at lower induced temperatures, drug
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uptake is facilitated and at higher induced temperature, complete cancer cell ablation is
possible.92
The goal of this study was to substantiate the theory that proven anticancer drugs, such as
PAC, could also be effectively housed within the AuNR-HSAPs, with efficient loading.
Subsequently, adequate PAC release via the PPTT heating of the hybrid particles was also
necessary for immediate additive treatment effects. This research supplies evidence that the
PAC-AuNR-HSAP hybrid delivery system offers simultaneous drug-release and PPTT as well as
extended, controlled further release of the drug over time. The PAC-AuNR-HSAPs have the
potential to be irradiated in the biologically safe water window (700-900 nm) in vivo at a tumor
site up to 10 cm below the skin without affecting surrounding healthy cells. 28, 93
This work shows drug-Au-HSAP hybrid composites with overall diameters of 299 ± 6 nm,
which have a conceivable future as flexible, multimodal platforms for the targeted detection,
contrast imaging and selective treatment of cancer and other diseases.32, 77
3.3

Experimental Methods

3.3.1 Materials and Reagents
Human serum albumin, lyophilized powder ≥ 97%, potassium bromide, Acrodisc® syringe
filters with nylon membrane (diam. 13 mm, pore size 0.2 μm), Corning Costar cell culture plates
(flat bottom, 12 well), and 8% aqueous glutaraldehyde were obtained from Sigma Aldrich (St.
Louis, MO). Ethanol (200-proof, ACS/USP grade) was obtained from Pharmco-AAPER (CT,
USA). Water was distilled, deionized, and then further purified with a Barnstead Nanopure
system.
Bare gold nanorods (10 nm average axial diameter, 43 nm average length, surface plasmon
resonance ~ 808-829 nm, OD = 1, 5.9 × 1011 AuNR/mL in water) were obtained from Nanopartz,
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Inc. (Loveland, CO). The AuNRs used were advertised by the vendor as bare, but they did
contain trace amounts of cetyltrimethylammonium bromide.
3.3.2

Synthesis of PAC-AuNR-HSAPs and PAC-HSAPs
The PAC-AuNR-HSAPs were prepared using a conventional desolvation technique

with the addition of AuNR seeding and drug loading. 20, 81, 83 The standard method for
preparation included creating an aqueous HSA stock solution (100 mg/mL). After dissolving,
the pH was around 7. To a portion of the HSA stock solution, an aliquot of the AuNR stock
solution was added, along with a small stir bar. From a paclitaxel stock solution (1 mg /mL
ethanol), an aliquot was added drop-wise to the AuNR/HSA solution flask at a rate of 1
mL/min using a peristaltic pump. Then, additional ethanol was added to achieve a final
solution containing 60% ethanol. Upon the addition of the ethanol, the solution became turbid.
Finally, an aliquot of 8% glutaraldehyde (aq.) was added to crosslink the PAC-AuNR-HSAPs.
After 24 h of stirring, the particles were centrifuged at 13,000 rpm (16,060 g) for 20 minutes.
The supernatant was removed, filtered using a 0.2 µm syringe filter and saved for HPLC
analysis. The remaining particle pellet was resuspended in a wash solution of 2:3 water:ethanol
via ultrasonication. The particles were washed twice using 2:3 water:ethanol and the
supernatants were saved for HPLC analysis. The washed particles were stored at 4 °C in water.
The PAC-HSAPs were created by the same process as the PAC-AuNR-HSAPs, with an aliquot
of pure water substituted for the AuNR stock solution.
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3.3.3

HPLC

The HPLC system used to analyze the paclitaxel was an Agilent 1100 instrument (Palo Alto,
CA) with a diode array absorbance detector. The column was an Agilent Eclipse XDB-C18
column (150 X 4.6 mm, particle size 5μm). The injection volume was 100 μL, and the
wavelength used for quantitation was 227 nm. The solvent mobile phase was 45% acetonitrile
and 55% water at a flow rate of 1 mL/min. The elution time for the PAC was approximately 3.8
minutes. Total entrapment of the drug was determined as the total mass of drug added to the
particles minus the combined mass of drug in the supernatant and washes.
3.3.4

Dynamic Light Scattering

The HSAPs were characterized by measuring their diameter, mobility, and zeta potential
using a Mobius dynamic light scattering (DLS) instrument (Wyatt Technology Corporation,
Santa Barbara, CA). Samples were diluted with water prior to analysis.
3.3.5

Laser Irradiation of Particles

The PAC-AuNR-HSAPs and PAC-HSAPs were tested for heating ability and drug release
under laser irradiation. To heat the samples, 1 mL of the sample was placed into a well of a 12well plate. The plate was placed approximately 4 inches under a vertically mounted laser. A
LabSpec 808 nm collimated diode laser system was used at a continuous wave power output of
2000 mW for 15 or 30 minutes for each sample. The size of the beam was approximately 1 × 1
cm. Temperature changes caused by the irradiation sessions were measured using a Spark
Science Learning System™ model PS-2008A thermocouple.
After irradiation, the contents of the wells were collected and centrifuged at 13,000 RPM for
15 minutes. The resulting supernatant was collected, diluted with ethanol, filtered, and saved for
HPLC analysis.
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3.3.6

SEM and TEM

Particles were imaged using a field emission-scanning electron microscope FESEM, LEO
1530VP (LEO Elektronenmikroskopie GmbH, Oberkochen, Germany). HSAPs were sputtered
with a thin film of gold or silver to facilitate imaging. Transmission electron microscope (TEM)
images were acquired with a JEOL Model 2010 TEM.
3.4

Results and Discussion

3.4.1 Formation of PAC-HSAPs and PAC-AuNR-HSAPs
Desolvation is a simple, thermodynamically driven self-assembly process for polymeric
materials by the addition of a denaturing agent, which coacervates the polypeptide molecules in
the aqueous phase, thus facilitating electrostatic and hydrophobic interactions.14 DLS confirmed
that the average particle sizes for PAC-HSAPs with no AuNRs inside (using 30 mg HSA) was
158 ± 7 nm and PAC-AuNR-HSAPs were 331 ± 3, 299 ± 6 and 212 ± 28 nm when starting the
preparation process with either 20, 30 or 50 mg HSA, respectively (while all other preparation
parameters were held constant). When AuNRs were present, the overall average HSAP size
increased; likely due to the AuNRs acting as seeds, taking up internal space in the HSAP, thus
facilitating more HSA available for continued particle growth.
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a.

b.

Figure 3.1. AuNR-HSAPs created with 2 mg of HSA and 2 mL of AuNR stock solution
visualized via (a) FESEM image and (b) TEM image showing the AuNRs within.

There was also a trend of decreasing AuNR-HSAP size as the amount of protein available
was increased from 20 to 30 to 50 mg. This size decrease is likely due to the fact that more HSA
present allows for continued new particle formation after all AuNRs have been encapsulated;
thus creating a greater number of smaller unloaded-HSAPs and a smaller average particle size.
Therefore, the AuNR-HSAPs present are smaller overall, but with more polydispersity.
Figure 3.1 provides representational SEM and TEM images of the AuNR-HSAPs created
with only 2 mg of HSA and 2 mL AuNR stock solution. (For imaging purposes, more heavily
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AuNR loaded particles with larger sizes are shown here, whereas the same amount of AuNRs
loaded into 20, 30 or 50 mg of HSA would result in a TEM image of largely unloaded-HSAPs
amongst the AuNR-HSAPs.) The PAC-AuNR-HSAPs created with either 20, 30 or 50 mg of
HSA had zeta potential values of ζ = -38 ± 1, -42 ± 3 or -45 ± 3 mV, respectively; showing
highly stable particle formations; since colloids are generally very stable when ζ > +25 mV or ζ
< -25 mV.
Aside from EPR effects mentioned previously, studies have shown that albumin-bound
paclitaxel binds to the gp60 HSA receptor on the cell surface, facilitating transcytosis via the
formation of caveolae; thus causing increased uptake of PAC into diseased cells.94 Our
formation of bio-friendly particles are not only efficiently sized for EPR effects, but they also
have the potential to mitigate damage to healthy cell membranes caused by toxic CTAB-coated
AuNRs.95 Since any residual CTAB is hidden by the HSAP shell, the toxicity caused by CTAB
should be reduced.
3.4.2

Loading Efficiency of PAC into HSAPs and AuNR-HSAPs

The aim of this project was to create PAC-AuNR-HSAP composite particles for potential
future use in PPTT. Because gold is readily coordinated by sulfur-containing moieties in the
albumin (resulting in Au-albumin thiol bonds), we, and other researchers, have previously seen
that the albumin coats the surface of the gold.95, 96 This protein corona layer results in the gold
particles which act as nuclei during coacervation of the AuNR-HSAPs.
To test whether the presence of AuNRs hindered the drug encapsulation ability of the
HSAPs, 0.5 mg of PAC was added to separate particle batches consisting of either 30 mg of
HSA or 30 mg HSA and 1.5 mL AuNRs solution. It was found that the PAC-HSAPs and the
PAC-AuNR-HSAPs entrapped an average of 63.3 ± 14 and 91.8 ± 9 µg of PAC, respectively.
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There was a 45% increase in PAC loading when AuNRs were present in the particles. This was a
surprising result and it is not fully known what caused this increase in PAC loading when
AuNRs were present.
We speculate that the PAC could have adsorbed onto the AuNRs (due to a hydrophobic
interaction with the trace CTAB present) prior to and during the formation of the HSA corona
layer. Previous research has shown that the ammonium group of one CTAB binds to the surface
of the gold and the hydrocarbon chain can interact with another CTAB’s hydrocarbon chain.
The second CTAB’s ammonium group is positively charged and free to bind to HSA. The
hydrophobic pocket created in between the two CTAB molecules is free to bind drug. Then, the
amphiphilic properties of the HSA packing around the gold may have reinforced the PAC
placement. 28
To find the loading efficiency of the paclitaxel in the PAC-AuNR-HSAPs, the preparation
procedure in Section 3.3.2 was followed with two distinct experimental changes: 1) the mass of
HSA remained the same and the mass of PAC was varied and 2) the mass of HSA was varied
and mg the mass of PAC remained constant. Figure 3.2a shows the results when 30 mg of HSA
were prepared with either 0.1, 0.25 or 0.5 mg of PAC and the resulting PAC-AuNR-HSAPs
were successfully loaded with 17 ± 2, 39 ± 5 and 92 ± 14 µg of PAC, respectively. The
particles created with 0.5 mg PAC contained over 3 µg of drug per mg of HSA in finished
particles.
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Figure 3.2. (a) 30 mg of HSA was prepared with either 0.1, 0.25 or 0.5 mg of PAC: (solid line)
µg of PAC loaded into the PAC-AuNR-HSAPs vs. the mg of PAC initially added to the
preparation vial and (dashed line) the percentage of loaded PAC vs. PAC added to the
preparation solution. (b) 0.5 mg PAC was added to particle preparation batches containing either
20, 30 or 50 mg HSA (solid line) µg of PAC loaded into the PAC-AuNR-HSAPs vs. the mg of
HSA present in the preparation vial and (dashed line) the percentage of loaded PAC vs. PAC
added to the preparation solution when HSA is varied.

Since the final particle suspension was in a volume of 1 mL, the resulting concentration of
drug in the suspension was 133 µM. This concentration is the amount of drug entrapped within
the batch of particles and can potentially be released to the tumor site via PPTT and temporally
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during dynamic enzymatic activity in vivo. That loading concentration far exceeds the in vitro
cytotoxicity of a paclitaxel-filled lipid emulsion in a previous study, which was shown to have
a paclitaxel IC50 value of 5.5 µM on HeLa cells.97 The IC50 value is the half maximum
inhibitory concentration, which is determined by a dose-response curve, and it indicates the
concentration of drug that is required for 50% inhibition of the cancer cells in vitro.98
Figure 3.2b shows results when 0.5 mg PAC was added to particle preparation batches
containing either 20, 30 or 50 mg HSA. The resulting drug loading was 56 ± 14, 92 ± 14 and
93 ± 20 µg PAC, respectively. There was a larger increase in drug loading when increasing
mass of HSA in the sample from 20 to 30 mg HSA; followed by a plateu in PAC loading when
using 30 or 50 mg HSA. The 30 mg HSA sample was still able to hold the most drug per mg of
HSA: 3 µg PAC/mg HSA.
The % PAC loading data shown in Figures 2a and 2b confirm the particles do not entrap
more than roughly 17% of the 0.5 mg PAC added to the preparation solution, even when more
HSA is available. This result was not fully understood, except for the hypothesis that the
crosslinking of these particles might be playing a role in the effective drug entrapment as both
the 30 mg and 50 mg particle batches were theoretically crosslinked at 40%.
3.4.3

Effect of Crosslinking on Drug Loading

The amine groups on the HSA are crosslinked by a condensation reaction with the aldehyde
groups of glutaraldehyde.20 It has been calculated that the lowest required amount of
glutaraldehyde needed to quantitatively crosslink all 59 ε-amino groups present in 100 mg of
HSA is approximately 58.8 μL of 8% (V/V) glutaraldehyde (4.7 × 10-5 moles) in H2O. 20 All
theoretical crosslinking calculations were based on this previous work and it has been customary
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for groups working with this desolvation and crosslinking process to use percentage values to
indicate the expected degree of crosslinking.85
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Figure 3.3. Average µg of PAC loaded into PAC-AuNR-HSAPs vs. the % of theoretical
crosslinking of the particles. Error bars represent standard deviations of measurements (n > 3).

To test whether the crosslinking played a major role in drug loading, two sample preparations
of PAC-AuNR-HSAPs were created with 30 mg HSA and 0.5 mg PAC; one batch was
theoretically crosslinked at 20% (2.87 × 10-6 moles glutaraldehyde) and the other at 40% (5.73 ×
10-6 moles glutaraldehyde). As shown in Figure 3.3, the 40% crosslinked PAC-AuNR-HSAPs
had more drug loading (92 ± 14 μg) with less deviation, while the 20% crosslinked particles had
less consistent drug loading (53 ± 49 μg). Although, some batches of the 20% crosslinked
particles were capable of loading up to 102 μg of PAC, there was a large error associated with
the loading. Therefor crosslinking definitely plays a role in keeping the paclitaxel locked into
the particles until it is provoked for release.
3.4.4

PAC-AuNR-HSAP and AuNR-HSAP Heating Capabilities

It has previously been discovered that when AuNR induced PPTT is used to create
hyperthermia in human prostate tumor bearing mice, maintaining temperatures of 42-43˚C for 10
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minutes showed an increase of macromolecular delivery into the tumor site. 99 In a separate
study, when using paclitaxel-conjugated 11-mercaptoundecanoic acid-linked polyethylene glycol
coated AuNRs, a combination of the drug and heating to 58˚C left absolutely no viable A549
breast cancer cells. 28 Our approach allows for heating via selective temperature ranges,
depending on the dosage of the PAC-AuNR-HSAPs delivered and the NIR treatment time.
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Figure 3.4. Heating trend in ºC of (solid line) PAC-AuNR-HSAPs and (dashed line) PACHSAPs

A cell well-plate was placed under the vertically mounted laser and particle batches
suspended in water and ethanol were placed in the wells. The 808 nm laser was turned on at 2 W
of power for up to 15 minutes while a thermocouple, placed on the side of the well, recorded the
temperature continuously. The particle solution was then collected via a pipette, centrifuged and
the supernatant was saved for drug content analysis. Figure 3.4 shows the heating trend (solid
line) for PAC-AuNR-HSAPs created with 30 mg of HSA, 1.5 mL AuNR stock and 0.5 mg of
PAC. The particles experience a sharp increase to 43ºC in roughly 5 minutes and continue to 46º
within 15 minutes.
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The dashed line in Figure 3.4 represents the heating ability PAC-HSAPs with no AuNRs
inside; it is shown that these particles never reached a temperature over normal body
temperature. The graph clearly shows that the AuNRs are necessary to cause substantial heating.
Consequently, only cells with HASP-AuNR and exposure to laser radiation would experience
hyperthermia.
3.4.5

Drug Release via Photothermal Irradiation

Literature reports state that paclitaxel has cytotoxic activity at concentrations as low as 50
nM, and it was evident that the PAC-AuNR-HSAP delivery system was capable of loading far
more paclitaxel than that (up to 133 μM in a 1 mL sample, shown in Section 3.4.2), while still
maintaining heating abilities.100 The PAC-AuNR-HSAPs we created are true hybrids, where
the anticancer functions of PPTT aided-uptake, heat ablation, EPR and drug release coexist, so
it was important to know the heat-induced drug release. Our method must prove drug release
of at least the minimum cytotoxic dose via PPTT and temporal release in order to be a viable
treatment vehicle
In this study, the PAC-AuNR-HSAPs initially created with 0.1, 0.25 or 0.5 mg PAC (created
with 30 mg HSA and crosslinked 40%) were irradiated with 808 nm NIR light for 15 minutes to
monitor PAC release. These particles contained on average 56.1 ± 14, 91.8 ± 14 and 92.7 ± 20
µg PAC and after only 15 minutes, they released 189 ± 108, 111 ± 33 and 124 ± 70 ng,
respectively. In each case, a slight burst of release less than 1% of the loaded PAC was shown.
Although a small percentage, the induced release would be considered an effective dose, with the
lowest average concentration of 145 nM released into the 1 mL of irradiated solution. This is
actually a desirable outcome, as a quick complete release of the drug payload can result in lower
antitumor efficacy due to the subsequently quick drug clearance from the body.60 The ideal
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antitumor treatment would be to harness the initial shock of the heat ablation and paclitaxel dose
in a localized area, followed by the slower, continued release of the drug penetrating further into
the tumor site via the leaky vasculature and heightened metabolism of the site.
It is also worth noting that the particles which were created with different crosslinking
percentages showed differences in drug release as well. The PAC-AuNR-HSAPs created with
20% theoretical crosslinking released over 4% of the entrapped drug; an average of 932 ng
PAC released vs. 124 ng (less than 1%) released by the 40% crosslinked particles. As found
with the loading, there is a large statistical error for the drug release associated with the lesser
crosslinked particles: 932 ± 646 ng. The amount of drug that remains in the less tightly locked
particles has a better chance of being released.
Conversely, greater crosslinking allows for increased loading and the opportunity for
prolonged release as well as decreased chances of drug release in areas other than the tumor
site. These release results were compared to two control scenarios, where release was tested on
irradiated PAC-HSAPs containing drug, but no AuNRs and on PAC-AuNR-HSAPs which
were not irradiated. In both cases, the drug in the measured particle supernatant was below the
detection limit of 0.00001 mg PAC/ mL using HPLC analysis.
3.4.6

Temporal Drug Release

Finally, to show that the paclitaxel was indeed released continually from the PAC-AuNRHSAPs after the initial irradiation period, three separate batches of PAC-AuNR-HSAPs
samples (batches A, B and C) were created (each with 0.5 mg PAC and 40% crosslinking
preparation parameters) and irradiated for 15 minutes. For each batch, the sample suspensions
were centrifuged and the supernatants were removed for initial, laser provoked drug release
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analysis. Just as in Section 3.4.5, the initial burst of drug release for each sample batch was
below 1% of the total loaded drug.
The particle batches were then stored at 4 ºC for a certain amount of time: batch A was
stored for 7 days, batch B for 14 days and batch C for 21 days in order to monitor subsequent
drug release when no further irradiation is performed past the initial laser session. Figure 3.5
shows the release trend for the post-irradiated particles. Total drug released after 7, 14, and 21
days was 136 ± 22, 193 ± 36 and 224 ± 68 ng, respectively, for batches A, B and C. For
example, this means that after 7 days, samples in batch A experienced a further drug release of
136 ± 22 ng in addition to the initial drug release the samples had already experienced during
the irradiation session. Therefore, Figure 3.5 is not a cumulative representation of drug release
including the irradiation-provoked release, but rather it is a representation of how the PACAuNR-HSAPs are capable of extended drug release post initial PPTT treatment.
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Figure 3.5. Average ng of unprovoked PAC released vs. Time in days. Error bars represent
standard deviations of measurements (n > 3).
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This release was in water at a low temperature without irradiation, so it should be noted
that the dynamic activity of a tumor at normal body temperature and a slightly acidic pH (as
seen in tumor sites) will enhance the release rate. Even though PAC-HSAPs with no gold
nanorods inside did not experience an initial irradiation-provoked burst of drug release because
of their inability to sufficiently heat, the PAC-HSAPs did release 104 ± 22 ng over a 7 day
period, compared to 136 ± 22 for PAC-AuNR-HSAPs. This confirms that any particles which
do not end up with a gold nanorod inside will still complete the function of controlled drug
release over time.
What makes this even more promising is that PAC-HSAPs without AuNRs inside would
travel alongside the PAC-AuNR-HSAPs in vivo and they may still experience the heating
effects of the neighboring gold-filled particles. So, under biological conditions, the PACHSAPs may still experience the initial burst of drug release during irradiation as well as
undergo their temporal chemotherapeutic function.
3.5 Conclusions
In this study, hybrid PAC-AuNR-HSAPs were successfully prepared with simultaneously
loaded drug and encapsulated AuNRs to show that these composite particles can serve as
platforms for preparing new drug therapies. The combined approach will allow killing of cancer
cells by both hyperthermia and localized chemotherapy treatment and is more likely to eliminate
all cancer cells. The photothermal approach not only results in hyperthermic treatment, but it
also serves as a trigger for drug release once the particles have reached their targeted tissue and
may aid in controlled release only at the tumor site. Functionalizing the surface of the HSAPs
with disease-specific targeting ligands may lead to even more effective delivery of cancer
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therapies to the site of the disease, boosting effectiveness and reducing damage to healthy
tissue.42
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Chapter 4
Hybrid Gold Nanorod Human Serum Albumin Nanoparticles for
Photothermal Therapy of Renal Cell Carcinoma

4.1 Abstract
In this study, the desolvation and crosslinking approach was employed to successfully
encapsulate gold nanorods into HSAPs, forming AuNR-HSAPs (in accordance with Chapter 2)
for in vitro studies. For particles created with the same amount of AuNRs, but varying amounts
of HSA (1, 5 and 20 mg), the overall particle diameters were 409 ± 224, 294 ± 83 and 167 ± 4
nm, respectively. It was found that particles created with more protein result in a smaller, but
more controllable, desirable average diameter size. The particular AuNR-HSAPs in this chapter
were synthesized for specific use in the plasmonic photothermal therapy (PPTT) of renal cell
carcinoma (cell line 786-O), using 808 nm near-infrared laser irradiation. Dosing experiments
were done in vitro to determine the appropriate amount of unloaded-HSAPs and AuNR-HSAPs
which can be delivered to the cells with limited inherent toxicity when no laser treatment was
inflicted (dark treatments).
Irradiation treatments were also completed to test the dosing amount of AuNR-HSAPs
needed to facilitate sufficient temperatures for PPTT of the cancer cells. We found that even
though an increase in the relative amount of HSA present during preparation leads to more
unloaded-HSAPs present alongside the AuNR-HSAPs in the final particle suspension, it also
leads to an increase in heating capabilities. An increase in HSAPs delivered also leads to more
toxicity under dark treatment conditions. A dose of HSAPs/AuNR-HSAPs created with 20 mg
versus 5 mg of HSA caused dark cell viability percentages of 64.5% and 87%, respectively. All
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of the AuNR-HSAPs batches experienced photothermal heating of above 42 ˚C (sufficient for
moderate hyperthermia) when delivered to the cells in a 1 mL dose (all particles created in a
given batch). After the full irradiation time, an MTT assay showed the AuNR-HSAPs PPTT
effects: the strategy facilitated a significant decrease in cell viability to 0%.
An imaging dye, coumarin-6, was used to visualize the cell uptake of the AuNR-HSAPs
via fluorescence microscopy. The particles did become fluorescently labeled and the cells
showed signs of endocytosis when in contact with the AuNR-HSAPs. The system also lends
itself to future customizable external functionalities such as stealth travel throughout the body
and increased tumor uptake via conjugated targeting ligands. Internal entrapment of the
chemotherapeutic medication sorafenib is currently being tested and optimized for tandem
chemotherapeutic and photothermal therapies during a given treatment time. Animal models for
in vivo testing are also being arranged in the near future for more dynamic treatment
experiments.

59

4.2 Introduction
Renal cell carcinoma (RCC) is the most common kidney-based malignant tumor and it
does not respond to traditional chemotherapy and radiotherapy to the same extent as some other
tumor types.96 The most used method of treatment has been partial nephrectomy, where the
diseased portion of the kidney is removed. 92 This method is, of course, invasive and is
especially dangerous for elderly and health-compromised patients. Diagnostic advancements of
early-stage RCC have allowed for non-invasive treatments which spare much of the healthy
kidney tissue. 99
One such treatment is radiofrequency ablation, which uses a probe to inflict an alternating
electrical current that induces heating of greater than 60˚C, with optimal temperatures between
50-100˚C.99,101 If temperatures are too high (> 105˚C), the tissue can be charred; resulting in
reduced dissemination and tissue resistance. Uncontrolled heating can also result in reduced
renal function over time or uneven heating, nullifying the use of an alternative treatment.
Therefore, tumor recurrences after heating are a problem, especially in larger tumors and
radiofrequency ablation tends to require repeated ablations. 92, 101
Despite the successes of thermal ablation on RCC, uncontrolled or incomplete heating,
coupled with RCC’s increased drug resistance, calls for a better treatment method which delivers
the best of both therapy options. Human serum albumin nanoparticles (HSAPs) filled with gold
nanorods (AuNRs) form composite AuNR-HSAPs which offer a combative approach to solving
both treatment problems. The AuNR-HSAPs can offer biocompatible, controlled heating in a
specific location and the release of an increased dose of an otherwise dose-limiting
chemotherapeutic drug.
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In a previous study in Chapter 2, we focused on a proof-of-concept synthesis to fully
encapsulate gold nanorods into size-controlled HSAP spheres with the future goal of taking
advantage of the plasmonic photothermal therapy (PPTT) effects of the AuNRs without having
them susceptible to clearing the body as fast as drug-conjugated AuNRs.41 The hybrid particles
are drug-loading powerhouses capable of enhanced permeability and retention effects within a
tumor site. 8, 9, 10 In Chapter 3, we reached the goal of successfully encapsulating the anticancer
drug paclitaxel within the AuNR-HSAPs simultaneously with the AuNRs; with efficient loading.
That research supplied evidence that the PAC-AuNR-HSAP hybrid delivery system offered
simultaneous drug-release and PPTT as well as extended, controlled release of the drug over
time.
The work in this chapter aimed to prove that the AuNR-HSAP hybrid composites
actually work to effectively kill cancer cells, without inherent toxicity, thus giving future purpose
and promise to our former successes of being able to create and load drugs into the particles.
Through fluorescence microscopy cell uptake studies and MTT cell assays, we show a definite
increase in cell death with the use of the AuNR-HSAPs as a PPTT vessel. Current studies on
loading AuNR-HSAPs with sorafenib, an angiogenesis inhibiting antitumor agent, are ongoing
and hold much promise for a complete hybrid SRF-AuNR-HSAP in the near future for use in the
RCC treatment of animal models. 60
4.3 Experimental Methods
4.3.1

Materials and Reagents

Human serum albumin, lyophilized powder ≥ 97%, potassium bromide, Acrodisc® syringe
filters with nylon membrane, diam. 13 mm, pore size 0.2 μm, Corning Costar cell culture plates,
12 well, flat bottom and 8% aqueous glutaraldehyde were obtained from Sigma Aldrich (St.
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Louis, MO). Ethanol, 200-proof, ACS/USP grade was obtained from Pharmco-AAPER (CT,
USA). Water was distilled, deionized, and then further purified with a Barnstead Nanopure
system. The renal cell carcinoma cell line, RPMI media, coumarin-6, and materials for the MTT
assay were supplied by Tulane University Medical Center.
Bare gold nanorods (10 nm average axial diameter, 43 nm average length, surface plasmon
resonance ~ 808-829 nm, OD = 1, 5.9 × 1011 AuNR/mL in water) were obtained from Nanopartz,
Inc. (Loveland, CO). The AuNRs used were advertised by the vendor as “bare”, but they did
contain trace amounts of cetyltrimethylammonium bromide.
4.3.2

Synthesis of AuNR-HSAPs
The AuNR-HSAPs were prepared using a conventional desolvation technique from

Chapter 2 with the addition of AuNRs for seeding. 20, 81, 83 The standard method for
preparation included creating an HSA stock solution of 100 mg HSA/ 1 mL of water. After
dissolving, the pH was around 7. To an aliquot of the HSA stock solution (containing 1, 5 or
20 mg of HSA), 2 mL (1.18 × 1012 AuNRs) of the AuNR stock solution was added, along with
a small stir bar. Then, 100% ethanol was added to a known volume to denature the protein and
facilitate aggregation. Upon addition of the ethanol, the solution became turbid. Finally, an
aliquot of 8% glutaraldehyde (aq.) was added to crosslink the AuNR-HSAPs. After 24 h of
stirring, the particles were centrifuged at 13,000 rpm (16,060 g) for 20 minutes. The
supernatant was removed and the remaining particle pellet was washed twice by resuspending
AuNR-HSAPs in water via ultrasonication. The final particles were redispersed and stored at 4
°C in water. The final particle suspensions were named by the amount of HSA in mg used in
the preparation process: 1-AuNR-HSAPs, 5-AuNR-HSAPs and 20-AuNR-HSAPs for 1, 5, and
20 mg HSA, respectively.
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4.3.3

Dynamic Light Scattering

The completed HSAPs were characterized by measuring the diameter, mobility, and zeta
potential using a Mobius dynamic light scattering (DLS) instrument (Wyatt Technology
Corporation, Santa Barbara, CA). Samples were diluted with water prior to analysis.
4.3.4

SEM and TEM

Particles were imaged using a field emission-scanning electron microscope FESEM, LEO
1530VP (LEO Elektronenmikroskopie GmbH, Oberkochen, Germany). HSAPs were sputtered
with a thin film of gold or silver to facilitate imaging. Transmission electron microscope (TEM)
images were acquired with a JEOL Model 2010 TEM.
4.3.5

Cell Line

RCC 786-O were incubated in 30, 1cm diameter wells. They were grown to approximately 7080% confluence in 1mL of RPMI media at a temperature of 37° Celsius and at 5.0% CO2, using
Forma ScientificTM CO2 Water Jacketed Incubator Model 3110 (115V, 3.6A, 50/60Hz).
4.3.6

Laser Irradiation of Particles

The final, washed AuNR-HSAPs and HSAPs were tested for heating ability and cell death
via laser irradiation. To heat the samples, an aliquot of the particle sample was placed into a well
of a 28-well plate containing renal cell carcinoma. The plate was placed approximately 4 to 6
inches under a vertically mounted laser. A LabSpec 808 nm collimated diode laser system was
used at a continuous wave power output of 2000mW for 30 minutes (irradiated) or zero minutes
(dark)for each sample. The size of the beam was approximately 1 × 1 cm. Temperature changes
caused by the irradiation sessions were measured using a Spark Science Learning System™
model PS-2008A thermocouple.
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The cells received a total of 1 mL of liquid: an aliquot of media and a dose of the AuHSAP suspension (50 µL, 0.5 mL or 1.0 mL) that contained either a control condition
containing no particles, unloaded-HSAPs, bare AuNRs or 1-, 5- or 20-AuNR-HSAPs. Every
batch of AuNR-HSAPs contained some HSAPs that formed with no gold nanorods within
them; therefore there is always a certain ratio of unloaded-HSAPs to AuNR-HSAPs in a batch.
For the preparation methods 1-AuNR-HSAPs, 5-AuNR-HSAPs and 20-AuNR-HSAPs (all
with 1.18 × 1012 AuNRs), the resulting finished particle batches contained varying ratios of
unloaded-HSAPs and AuNR-HSAPs. All samples were kept out of the incubator for the same
amount of time to ensure that no cells were protected from the effects of the environment any
more than cells currently being irradiated. After irradiation, the contents of the wells were
assayed via an MTT assay for cell viability testing.
4.3.6

MTT Assay

Cell viability after AuNR-HSAPs and HSAPs treatment was measured by MTT assay. The
assay used a tetrazolium compound (Sigma Aldrich, St. Louis, MO), which when reduced by
intracellular mitochondrial dehydrogenase enzyme, converts tetrazolium into purple formazan
indicating the magnitude of cell viability. The viability of cells post treatment was measured by
the quantification of purple formazan by colorimetric method using a spectrophotometer
(Beckman Coulter, Inc., Schaumburg, IL).
4.3.7

Cell Uptake Studies via Fluorescence Microscopy

RCC 786-O were incubated in 3 separate plates of 10mL of RPMI media at a temperature of
37° Celsius and at 5.0% CO2. An aliquot of 0.5 mL of unloaded-HSAPs, coumarin-6 loaded
AuNR-HSAPs was added and incubated for 24 hours before images were taken using an
Olympus IX70-S1F2 fluorescence microscope (220-240V, 1.8/0.8A, 50/60Hz) with an Olympus
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DP71 camera (12.5 megapixel) and Olympus BH2 RFL- T3 Power Supply (100-120V, ~2.8 A,
50-60Hz).
4.4 Results and Discussion
4.4.1 Formation of AuNR-HSAPs
Using the desolvation and crosslinking process discussed in Chapter 2 to create thiol
bonds between the AuNRs and the HSAPs, a self-assembly process facilitated the formation of
a spherical HSAPs (see Table 4.1) around the AuNRs with average particle size diameters of
409 ± 224, 294 ± 83 and 167 ± 4 nm when using 1-AuNR-HSAPs, 5-AuNR-HSAPs and 20AuNR-HSAPs, respectively. 14 The zeta potential values for those AuNR-HSAPs were -39 ±
3, -35± 4 and -33 ± 3 mV, respectively. It is evident from the size information that as the
mass of HSA increased, the average particle size became smaller, with less deviation. Since the
zeta potential values for these size distributions reflect stable particles, we are confident that
these fluctuations are actually large distributions in size and not reflections of sizable
aggregates.
When using 1-HSAPs, 5-HSAPs and 20-HSAPs without gold nanorods (see Table 4.1),
unloaded-HSAPs were created with average diameters of 400 ± 160, 182 ± 46 and 174 ± 3 nm,
respectively. The zeta potential values for the particles were -26 ± 8, -22 ± 8 and -35 ± 3 mV,
respectively. This size and zeta potential information for unloaded-HSAPs depict a trend of
smaller particle sizes for a given amount of protein when no Au rods are present, with the
exception of the particles created via 20-HSAPs. The deviations in size also decreased. The
zeta potential values continued to reflect stability of the particles, however the AuNR-HSAPs
showed greater stability than the unloaded-HSAPs. This stability increase was a desirable
result; as it reflects another benefit of the hybrid particle.
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Table 4.1. Particle sizes and zeta potential data for AuNP-HSAPs and Unloaded-HSAPs used on
RCC.
AuNR-HSAPs
mg HSA in
Avg. Diameter
Zeta Potential
Preparation Method
(nm)
(mV)
1
409 ± 224
-39 ± 3
5
294 ± 83
-35 ± 4
20
167 ± 4
-33 ± 3
a
Error represents one standard deviation with N ≥ 3.

Unloaded-HSAPs
Avg. Diameter
Zeta Potential
(nm)
(mV)
400 ± 160
-26 ± 8
182 ± 46
-22 ± 8
174 ± 3
-35 ± 3

When comparing this data to the initial size values obtained for AuNR-HSAPs in Chapter 2,
there are some size difference due to differences in crosslinking, ethanol volumes, mass of HSA
used and volume of stock AuNR solution used.
4.4.2

Unloaded-HSAP and AuNR-HSAP Dark Effects on Renal Cell Carcinoma

Upon dispersion of a prepared sample into water, the final volume was 1 mL of suspension.
In an attempt to find any inherent toxicity caused by the particles, dark experiments were
performed on the RCC using either 50 µL, 0.5 ml or 1.0 mL doses of the finished particle
batches. Table 4.2 displays the viability data for the ‘dark’ treatment for both Unloaded-HSAPs
and AuNR-HSAPs created with varying amounts of HSA. There is a definite correlation between
the number of particles placed onto the cells and cell death.
For the Unloaded-HSAPs, it is theorized that 20-HSAPs creates far more particles due to the
increase in protein available for particle formation, thus the cells may become overwhelmed by
the 1.0 mL full batch dose and the cell viability is only 13%. However, when the 20-HSAP
prepared particles were dosed with only 0.2 or 0.05 mL of the originally prepared 1 mL particle
suspension, the cell viability was 70 and 80%, respectively. This viability increase proves that it
is not the 20-HSAPs themselves that are toxic to the RCC, but it is the amount of particles
delivered which causes some toxicity.
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The 1-AuNR-HSAPs, 5-AuNR-HSAPs and 20-AuNR-HSAPs also caused a decrease
in cell viability with a 0.5 mL dose, with the 5-AuNR-HSAPs causing the least amount of cell
death at 87%. It is interesting that the viability does not change much from the 50 µL dose
when using the 5-AuNR-HSAPs preparation type. It is clear that using the entire batch of
particles, a 1.0 mL dose, is too much for the RCC to handle and nearly all cells are killed
without irradiation.
Table 4.2. ‘Dark’ Treatment: Cell Viability Data for RCC Dosed with 0.05, 0.5 or 1.0 mL of
Unloaded-HSAPs or AuNR-HSAPs of Varying HSA Amounts
% Cell Viability After ‘Dark’ Treatment
mg HSA in Sample
Amount of Unloaded-HSAPs or AuNR-HSAPs Sample
Preparation
Added to the RCC
50 µL
0.5 mL
1 mL
0 (Control)
100%
100%
100%
5-HSAPs
20-HSAPs

94%
-

-

1-AuNR-HSAPs
86%
53%
5-AuNR-HSAPs
84%
87%
20-AuNR-HSAPs
65%
Hash mark indicates no data available for a particular study.
4.4.3

13%
0.6%
2.9%
4.5%

Photothermal Irradiation Effects on Renal Cell Carcinoma

Understanding that the dose should be 0.5 mL or lower for a particular preparation method,
irradiation studies were still done with 50 µL, 0.5 mL and 1.0 mL doses. Initially, when 50 µL
of 1-AuNR-HSAPs, 5-AuNR-HSAPs and 20-AuNR-HSAPs were added to the cell wells, none
of the trials were able to decrease cell viabilities to below 37% or final temperatures above 44°C
when irradiated for 30 minutes. While that temperature may cause moderate hyperthermia,
temperatures above 46°C are needed to induce coagulative necrosis. 45, 93 It became evident that
the number of AuNRs had to be increased in order to reach sufficient heating, therefore the
number of AuNR-HSAPs had to be increased.
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An interesting trend as seen in Figure 4.1 was, despite the samples having equal amounts of
AuNRs present within the particles, the 20-AuNR-HSAPs samples were able to heat the cells to
the highest temperature. The reason for this phenomena is not exactly known, however it is
speculated that the HSAP acts as some sort of spacer for the rods, thus allowing them to be more
individually effected by the light. One study found that increased amount of AuNRs past 0.5 nM
has an adverse effect on heating because of increased light absorption and decreased
photothermal conversion. 45 When delivered in a 1.0 mL dose, the 20-AuNR-HSAPs
experienced heating up to 51˚C after only 5 minutes a temperature necessary to cause severe
cellular hyperthermia and necrosis.

Maximum Temperature (˚C)
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Figure 4.1. Heating Capabilities of AuNR-HSAP batches made with varying mg HSA and
heated in either 0.5 or 1.0 mL doses.

Table 4.3 displays the cell viability information for the irradiated cells treated with particles.
Minimal warming was experienced when the laser was directed at RCC that were not treated
with particles (control). The Unloaded-HSAPs also experienced minimal warming, with cell
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viability dropping to 92% for the irradiated study from 94% during the dark study. The 1.0 mL
dose of particles had already experienced almost complete cell death during the dark study, so
the increase in necrosis after irradiation was not surprising.
The true testament to the effectiveness of the irradiation on the AuNR-HSAPs was the 0.5
mL dose of all three sample preparation types. The 1-AuNR-HSAPs, 5-AuNR-HSAPs and 20AuNR-HSAPs all experienced decreases in the percentage of viable cells, as seen in Figure 4.2.

Table 4.3. 'Irradiated’ Treatment: Cell Viability Data for RCC Dosed with 0.05, 0.5 or 1.0 mL of
Unloaded-HSAPs or AuNR-HSAPs of Varying HSA Amounts
% Cell Viability After ‘Irradiated’ Treatment
mg HSA in Sample
Amount of Unloaded-HSAPs or AuNR-HSAPs Sample
Preparation
Added to the RCC
50 µL
0.5 mL
1 mL
0 (Control)
99.5%
99.5%
99.5%
5-HSAPs

92%

-

1-AuNR-HSAPs
86%
36%
5-AuNR-HSAPs
68%
25%
20-AuNR-HSAPs
3.6
Hash mark indicates no data available for a particular study.
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Figure 4.2. Percent viability of Renal Cell Carcinoma after 'dark' (red bars) or 'irradiated' (blue
bars) treatment using AuNR-HSAPs made with varying mg HSA: 1, 5 or 20 mg.

It is worth noting that bare AuNRs killed of over 35% of the cancer cells without irradiation.
Even though the nanorods are marketed as “bare”, with almost all CTAB washed off, there are
still some residual amounts which has been shown to exhibit cytotoxicity unless properly
encapsulated.80 A proof of concept trial using only the bare AuNRs reached 59.7C with 100%
cell kill. AuNRs produced both the highest temperatures and the highest rate of cell kill, but also
demonstrated cytotoxicity in the absence of irradiation, whereas 1-AuNR-HSAPs showed less
cell kill but also demonstrated less cytotoxicity. HSAPs alone and 1-AuNR-HSAPs did not
produce cell kill rates higher than 15%. Low doses (0.5 mL or less) of 20-AuNR-HSAPs seem
the best therapeutic option moving forward.
4.4.4

Fluorescence Cell Uptake Studies

In order to determine whether the HSAPs were indeed being taken into the RCCs, a
fluorescence uptake study was performed using coumarin-6 dye as a label. Particles created via
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5-AuNR-HSAP were prepared in the presence of the dye. Figure 4.3 shows the fluorescence
microscopy of the coumarin-6 labeled AuNR-HSAPs after incubation with the renal cell
carcinoma. The particles are underwent endocytosis but were taken up into the cell nucleus.
Coupled with the irradiation data, these results are promising and display sufficient evidence that
the AuNR-HSAPs will be in close enough proximity to diseased cells to cause necessary
temperature increases upon irradiation in vivo.

Figure 4.3. (a) Confocal Microscope image of Renal Cell Carcinoma Treated with coumarin-6
labeled AuNR-HSAP-5 and (b) the fluorescence emission of the same cells.

4.5 Conclusions
In this study, hybrid AuNR-HSAPs were successfully prepared and showed more
controllable size distributions when more protein is added to the preparation vial. The particles
were able to heat to necessary temperatures in order to cause renal cell carcinoma death, but
careful consideration of the particle dose has to be maintained in order to not overwhelm the
cells without irradiation. This incidence of dark condition cell death may not matter very much
in a tumor site, however necrosis of healthy cells surrounding the tumor site must be avoided
during the time it takes for all of the AuNR-HSAPs to become trapped in the tumor vasculature.
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Since, fluorescence microscopy showed that the cells were taking up the AuNR-HSAPS,
functionalizing the surface of the HSAPs with disease-specific targeting ligands may lead to
even more effective delivery of cancer therapies to the site of the disease, boosting effectiveness
and reducing damage to healthy tissue. 42
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Chapter 5
Loading CPT (camptothecin) and BACPT (7-butyl-10-aminocamptothecin)
Into Human Serum Albumin Nanoparticles for use as a Targeted Therapy
Platform

5.1 Abstract
Camptothecin, a natural antineoplastic agent, and BACPT (7-butyl-10aminocamptothecin), an analogue of camptothecin (CPT), have garnered attention in the medical
field due to their high effectiveness against pancreatic, lung and ovarian cancers, however due to
their water insolubility, they has been lacking in fulfilling their potential as major anti-cancer
pharmaceuticals unless they have been manipulated in some way. Manipulations such as creation
of a prodrug or attachment of solubility ligands cause a decrease in the effectiveness of the drugs
and there is still a problem of toxicity. Camptothecin and BACPT also possess a propensity to
open their lactone rings in the presence of water forming a carboxylated version of the drug,
which some research suggests, causes some loss in effectiveness. Carboxylated camptothecins
also possess a high binding affinity for HSA, so are susceptible to being carried away from the
tumor site prematurely by molecular HSA, causing reduced efficacy.
However, there is evidence that, when in high enough concentrations, the carboxylate
form of camptothecins have the ability to effectively kill or slow the growth of cancer cells as
well as the lactone form. By taking advantage of the CPT’s and BACPT’s affinities to HSA and
entrapping the BACPT within human serum albumin nanoparticles (HSAPs), which have had
success as a colloidal carrier system for targeted treatment of cancer, the amount of drug that
reaches the cancer site can be greatly enhanced. This enhancement can potentially increase
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efficacy, safety and treatment success. HPLC and fluorescence spectroscopy were used to
determine drug loading efficiency.
Both the CPT-HSAPs and the BACPT-HSAPs showed toxicity to human sarcoma cells in
vitro. However, finding the drug loading amounts that caused the desirable toxicity was a
challenge. HPLC proved unreliable as an analytical technique for CPT and BACPT due to
inconsistent results from lactone conversion during the mobile phase. CPT could not be
determined via fluorescence spectroscopy as well due to sporadic, uncontrollable changes in the
fluorescence emission. The loading of BACPT into BACPT-HSAPs was determined via HPLC
and fluorescence spectroscopy and compared.
This research reports an efficient strategy for preparing 200-300 nm, size-controlled
BACPT-HSAPs with up to 5.25 micrograms of BACPT/ mg of HSA, as determined by
fluorescence spectroscopy. The BACPT-HSAPs showed evidence of cell necrosis for human
sarcoma cancer cells during in vitro studies. This proof of concept research shows that BACPTHSAPs are effective at killing cancer cells when the BACPT is present in both carboxylate and
lactone forms. The strategy also enables maximum external surface area for future
functionalization of targeting ligands for stealth-like disease detection.
5.2 Introduction
Camptothecins are used on primary and metastatic colon carcinoma, platinum-refractory
ovarian cancer, and small cell lung carcinoma. It acts by poisoning the DNA target enzyme
topoisomerase I (top I) during its catalytic cycle of DNA relaxation, leading to the generation of
DNA double-strand breaks and cell death by apoptosis.46,48,49,50 BACPT, 7-butyl-10aminocamptothecin (Figure 5.1), was developed in an effort to improve potency and crossresistance profiles of camptothecins.54 BACPT is promising because it has been found that a
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substitution at the C-10 position (See Figure 5.1) increases lipophilicity while substitution at the
C-7 position enhances potency in vitro. When binding to DNA, BACPT intercalates at the site of
DNA cleavage and is stabilized by an E-ring hydrogen bond contact with an aspartic acid.

54,55

The A-ring’s amine at the C-10 position also forms a hydrogen bond to an oxygen atom of the
side chain of a glutamine moiety. The C7- butyl moiety causes a very good steric fit of BACPT
with the top I enzyme, and the planar ring system of the drug mimics a DNA base-pair.54,55
These effects correlate with increasing persistence of the DNA cleavage complex created
by BACPT.54,55 Hiding the highly effective BACPT and CPT in a biocompatible protein sheild
in concentrations high enough to overcome the effects of the reduced lactone version will
accomplish the task of maximizing efficiency while minimizing harmful effects.
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C

Figure 5.1. BACPT
There has been some debate as to whether the antitumor activity is fully lost when a
camptothecins undergo a transforation to the carboxylate verion after they come into contact
with physiological pH and the structure of a blood protein such as HSA or if the process is
indeed a reversible process (Figure 5.2). 102 However, studies have shown evidence to suggest
that a significant amount (33% at pH 7.4, 66% at pH 6.8) of uncharged carboxylated BACPT
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could enter tumor cells at acidic pH and accumulate in mitochondria to inhibit mitochondrial top
I. 58 This is compared to the lactone form where 83-100% of the BACPT remains uncharged. 58
It has also been demonstrated that the carboxylate version of camptothecin sodium has been
effective against L1210 leukemia and carboxylate topotecan can bind to top I. 103, 104 A recent
study proved that the inhibitory rate of tumor percent caused by 9-nitrocamptothecin was
significant down to 25% lactone (vs. carboxylate) in tumor bearing mice. 105 The pH sensitive
antitumor drug is desirable because it can exploit the pH gradient which exists in solid tumors
but not in normal tissues 106.

Figure 5.2. Structure of CPT at physiological versus acidic pH.

The innovation of this project is the strategic use of HSAP’s enhanced permeation and
retention effects to entrap the aggressive, insoluble CPT and BACPT for more concentrated
release at a tumor site; increasing the dosage safely. The CPT/BACPT must be in continuous
contact with replicating cancer cells to be optimally therapeutic, therefore keeping the drug in
constant release, even in carboxylate form, in the acidic tumor is desirable. 105, 107 In this study, a
desolvation and crosslinking entrapment method facilitated size-controlled HSAP shells for
efficient internal enclosure of BACPT and CPT, as well as maximum external surface area for
future functionalizing of targeting ligands for disease detection. We have used an in vitro human
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sarcoma cell culture as a preliminary study of the effectiveness of BACPT-HSAPs for cancer
treatment. 108
5.3 Experimental Methods
5.3.1 Materials and Reagents
Human serum albumin, lyophilized powder ≥ 97%, 8% aqueous glutaraldehyde, RPMI
1640, porcine trypsin - 1X Solution, fetal bovine serum, streptomycin and amphotericin, were
obtained from Sigma Aldrich (St. Louis, MO). Ethanol, 200-proof, ACS/USP grade was
obtained from Pharmco-AAPER (CT, USA), Phosphate buffer (pH 7.2) and a Mini-Pump
Variable Flow peristaltic pump were obtained from VWR International (Radnor, PA). An
AccuSpin Micro centrifuge was obtained from Fisher Scientific (Pittsburg, PA). Water was
distilled, deionized, and then further purified with a Barnstead Nanopure system. Camptothecin
(S) (+) was obtained from VWR and BACPT was obtained from Dekk-Tec, Inc. (New Orleans,
LA). Cells: “CL” Human Sarcoma, cultured from a patient; Brain Dekk-Tec. Inc., 725 Topaz St,
New Orleans, LA)
5.3.2

Synthesis of Unloaded HSAPs

The HSAPs were prepared using a conventional desolvation technique.6, 15, 82, 81, 83 The
standard method for preparation included addition of 20 mg of solid HSA to 1 mL of water .
After dissolving, the pH was around 7. A small stir bar was added to the solution, and 3 mL of
100% ethanol was added at a rate of 1 mL/min using a peristaltic pump. Upon addition of the
ethanol, the solution became turbid. Finally, 4.7 μL of 8% glutaraldehyde (aq.) was added to
crosslink the HSA within the particles. After 24 h of stirring at room temperature, the particles
were centrifuged at 13,000 rpm (16,060 g) for 30 minutes to 1 hour. The supernatant was
removed and the remaining pellet was ultrasonicated and resuspended. The suspension was
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washed twice with water with intervening centrifugation steps. The washed particles were
ultrasonicated in water and stored at 4 °C.
5.3.3

Synthesis of BACPT-HSAPs

The procedure for preparing the drug-loaded particles followed section 5.3.2 with a
modification to the ethanol addition step and final volume. To create the BACPT loaded
HSAPs, a stock solution of the BACPT was first created: 1 mg BACPT/mL ethanol. Then, an
aliquot of the drug stock solution was added to more ethanol. The BACPT/EtOH solution was
added to an HSA sample solution drop-wise. The overall parameters used for preparing HSAPs
loaded with varying amounts of BACPT are provided in Table 5.1 (all samples contained 4.7
µL of 8% glutaraldehyde; causing 40% theoretical crosslinking). The washes for the drugloaded particles were done with a solution of 1:3 water:ethanol.
Table 5.1. Preparation Parameters for all BACPT-loaded HSAPs

5.3.4

Sample

Drug Stock

EtOH

Drug Added

Preparation Type

Solution (mL)

(~mL)

(mg)

BACPT-HSAP-1

0.01

3.99

0.01

BACPT-HSAP-2

0.1

3.9

0.1

BACPT-HSAP-3

0.25

3.75

0.25

BACPT-HSAP-4

0.5

3.5

0.5

BACPT-HSAP-5

1

3.0

1

Synthesis of CPT-HSAPs

The procedure for preparing the drug-loaded particles followed section 5.3.2 with a
modification to the ethanol addition step and final volume. To create the CPT loaded HSAPs, a
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stock solution of the CPT was first created: 1 mg CPT/mL in 2:3 chloroform:ethanol. Then, an
aliquot of the drug stock solution was added to more ethanol. The CPT/EtOH solution was
added to an HSA sample solution drop-wise. The overall parameters used for preparing HSAPs
loaded with varying amounts of CPT are provided in Table 5.2 (all samples contained 4.7 µL
of 8% glutaraldehyde; causing 40% theoretical crosslinking). The washes for the drug-loaded
particles were done with a solution of 1:3 water:ethanol.
Table 5.2. Preparation Parameters for all CPT-loaded HSAPs

5.3.5

Sample

Drug Stock

EtOH

Drug Added

Preparation Type

Solution (mL)

(~mL)

(mg)

CPT-HSAP-1

0.1

3.9

0.1

CPT-HSAP-2

0.25

3.75

0.25

CPT-HSAP-3

0.5

3.5

0.5

Absorbance

Absorbance measurements of the BACPT-HSAPs were performed with a Cary 60
absorbance spectrometer (Agilent Technologies).
5.3.6 HPLC
The HPLC system used was an Agilent 1100 instrument (Palo Alto, CA) with a diode array
absorbance detector. The column was an Agilent Eclipse XDB-C18 column (150 X 4.6 mm,
particle size 5μm). The injection volume was 200 μL, and the absorbance wavelength used for
quantitation of BACPT was 227 nm and for CPT it was 254 nm. The mobile phase was 60%
acetonitrile: 40% water at a flow rate of 1 mL/minute.
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5.3.7

Fluorescence

Fluorescence was measured with a Cary Eclipse fluorometer with excitation for BACPT at
403 nm and emission scanned from 413-600 nm. For CPT, the excitation wavelength was 358
nm and the emission was scanned from 368-550 nm. Excitation and emission slits were 2.5 nm.
5.3.8

Dynamic Light Scattering

The completed HSAPs were characterized by measuring the diameter, mobility, and zeta
potential using a Mobius dynamic light scattering (DLS) instrument (Wyatt Technology
Corporation, Santa Barbara, CA). Samples were diluted with water prior to analysis.
5.3.9

Microscopy

Particles were imaged using a field emission-scanning electron microscope FESEM, LEO
1530VP (LEO Elektronenmikroskopie GmbH, Oberkochen, Germany). HSAPs were sputtered
with a thin film of gold or silver to facilitate imaging. To check cell vitality after the addition of
nanoparticles to the cancer cells, a compound microscope was used; Meiji Techno, TC5300,
Compound - 100x on large view, 200x in zoom view, (Meiji Techno America, San Jose, CA)
5.3.10 Cell Cultures
Cell vitality studies were performed by two different methods.
CELL METHOD 1. For visual cytotoxicity studies without washing off unloaded-HSAPs,
CPT-HSAPs or BACPT-HSAPs: On a 12-well cell plate, to the each well, 1 mL of sterile RPMI
media was added, then, 1-drop aliquots of diluted (with RPMI) or undiluted harvested cell
solutions were placed into every well. The well plates were incubated at 37°C for 24 hours to
facilitate cell growth. After the 24 hour period, addition of the nanoparticles was accomplished
by adding 0.5 ml of the particle solution being tested; either unloaded-HSAPs or a particular
concentration of CPT-HSAPs or BACPT-HSAPs. The control was a well containing only cells
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and no nanoparticles. After the plates were incubated again with the particles at 37°C for 24
hours, the cells were visually checked for blebbing and necrosis on the compound microscope;
with the nanoparticles still present.
CELL METHOD 2. For visual cytotoxicity studies involving field of view differences after
washing the wells of nanoparticles and dead cells: the well plates were prepared as they were in
cell method 1, but after the initial incubation period, only 0.1 mL of particle solution being tested
was added. A control of cells only was prepared a well. After 24 hours of incubation, the wells
were removed of all particles and dead cells by pipetting off all media in which they were
incubated. The wells were washed twice with 1 mL of fresh RPMI. Any remaining cells were
viable and stuck to the well plate. Dead cells were washed away. A visual inspection on the
compound microscope showed differences in the live cell population of the control and the
treated wells.
5.4 Results and Discussion
5.4.1 Formation and Characterization of BACPT-HSANPs
The same thermodynamically driven self-assembly process for polymeric materials was used
in this chapter and proceeded by the addition of a denaturing agent to denature HSA in the
aqueous phase, causing aggregation, thus facilitating electrostatic and hydrophobic
interactions.14,18
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Figure 5.3. FESEM images of BACPT-HSANPs.

This process yielded samples with a size of 248 ± 66 nm, therefore it was assumed that the
BACPT-HSAPs created under similar desolvation parameters would yield roughly the same
particle size. That hypothesis proved correct. All five BACPT-HSAP preparation methods
yielded average size measurements within 227 ± 19 and 247 ± 30 nm. Figure 5.3 is an FESEM
image of BACPT-HSAPs showing that particles created in the presence of BACPT do not lose
their characteristic spherical shape or size. These BACPT-HSAPs created were still in a proven
effective size range for use as a targeted treatment vehicle.
BACPT-HSAPs created were still in a proven effective size range for use as a targeted
treatment vehicle.
Table 5.3. Preparation Type vs. Overall size of Completed BACPT-HSAPs
Sample Preparation Type
BACPT-HSAP-1
BACPT-HSAP-2
BACPT-HSAP-3
BACPT-HSAP-4
BACPT-HSAP-5

Drug Added (mg)
0.01
0.1
0.25
0.5
1
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Average BACPT-HSAP Size (nm)
234 ± 42
235 ± 20
242 ± 5
227 ± 19
247 ± 30

The overall average particle sizes for loading scenarios 1 thru 5 do not vary drastically, as
seen in Table 5.3. This research focuses on entrapping the BACPT described above into a shell
of HSAP big enough to also bind and hold an extremely high, maximum payload of drug while
succumbing to the EPR effects that will cause it to be trapped in a cancerous matrix, so the
consistent particle size is desirable.
5.4.2

Determination of Loading Efficiency of BACPT via HPLC

It was a concern that using HPLC as a quantitation method would not be an accurate
representation of the amount of drug washed off of the particles because the HPLC mobile phase
contains water. As discussed previously, water (at neutral pH) has the ability to open the
BACPT’s lactone ring (as seen in Figure 5.3), thus causing the structure of the BACPT to
change, potentially resulting in a shift of the characteristic peak. Figure 5.4 shows absorbance
spectra of 0.5 mg/mL solutions of a BACPT. The dashed line represents the absorbance of a
solution of BACPT in 1:4 water: ethanol; consistent with the solvent matrix in the particle
preparation supernatant. The solid line represents the absorbance of BACPT in 50:50 water:
ethanol; consistent with a “wash”. It is clear that there is absorbance spectrum shift with the
addition of more water in the BACPT matrix. This could affect the HPLC results, along with the
conformational change in the BACPT molecule which is responsible for the shift.
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Figure 5.4. Absorbance spectra of (solid line) 0.5 mg/mL BACPT in 50:50 water:ethanol and
(dashed line) 0.5 mg/mL BACPT in 1:4 water:ethanol.

Despite the shift, we sought to find out if HPLC could achieve drug quantitation in the
initial supernatant and subsequent particle washes. HPLC analysis of the particle preparation
supernatant and wash solutions were compared to a set of drug solution standards in 1:3
water:ethanol to mimic the matrix of the preparation solution. Figure 5.5 shows an HPLC
spectrum for a sample created with the BACPT-HSAP-4 preparation parameters (0.5 mg of
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BACPT added) and revealing a BACPT peak at 5.3 minutes.

Figure 5.5. HPLC spectrum of the initial centrifugal supernatant from a sample created with 0.5
mg BACPT. The BACPT manifests a peak at 5.3 minutes.

As discussed previously, water and its neutral pH has the ability to open the BACPT’s
lactone ring, thus causing the structure of the BACPT to change, potentially resulting in a shift of
the characteristic peak. It was indeed noted that the longer the samples (and standards) were
allowed to sit (even refrigerated), there was a reduction of the ~ 5 minute peak area. When
samples were compared to older standards, there was an undesirable finding of the calculated
drug washed off of the particles being higher than the amount of drug actually added to the
sample during preparation.
Given the impossibility of this result being accurate, all samples had to be analyzed within 48
hours of preparation and again, the washes could not be done with water alone but with an
ethanol mixture. Upon HPLC analysis of BACPT-HSAPs prepared by either, BACPT-HSAP-1,
BACPT-HSAP-4 or BACPT-HSAP-5, there was an increase in drug loading.
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Figure 5.6. Relationship of starting mg BACPT added to a particle batch compared to the mg
BACPT trapped within the particles in that batch. The measurements shown are the average
calculated values of drug trapped for the preparation types BACPT-HSAP-1, BACPT-HSAP-4
and BACPT-HSAP-5.

Figure 5.6 shows the relationship created by comparing the mg of BACPT added to the initial
formation solution and the calculated mg of BACPT trapped within the HSAPs, as determined
via HPLC. The average loading of BACPT into HSAPs when 0.01, 0.5 and 1.0 mg of BACPT
was added to a preparation solution was 3.8, 112.1 and 281.8 mg BACPT, respectively. This is a
final average drug concentration range of 3.8 to 281.8 µg/mL if the particles are resuspended in 1
mL of water. The particle solutions had resulting BACPT concentrations ranging 9.1 to 671 nM.
In each batch, the amount of HSA remained unchanged at 20 mg, therefore, there is clear
evidence that the HSAPs can hold an increasing amount of BACPT, but never all of the BACPT
added. There is a loading factor taking place here that is not clearly known. What is clear
however, is that further increasing the amount of BACPT into the preparation solution should
continue to increase the amount of BACPT capable of being trapped within 20 mg of HSAP until
86

a plateau is reached at max loading capacity. In an effort to spare resources, we did not
investigate this loading maximum, as it has been shown that BACPT concentrations in the
μmol/L range have been sufficient for cell death. 52, 55
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Figure 5.7. Relationship between mg BACPT added to formation solution and (solid line) mg
BACPT trapped in the particle batch and (dashed line) % of BACPT loading efficiency. The
measurements shown are the average calculated values for the preparation types BACPT-HSAP1, BACPT-HSAP-4 and BACPT-HSAP-5.

Figure 4.7 further illustrates the loading dynamics by showing that although the amount of
drug increases with increased mg BACPT added to the formation solution (which might be
expected), the percentage of drug loaded does not increase; decreasing from roughly 38-22%
loading. This decrease confirms the idea of a loading plateau for 20 mg of HSAPs and may
indicate some kind of binding competition or other kinetic influence. It was initially thought that
as the amount of BACPT added to the formation solution decreased, the percentage of drug
loaded should increase until all of the available drug was trapped inside, but the results dictated
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that only a percentage of the available drug is binding to the HSA during BACPT-HSAP
formation.

Avg. Particle Size (nm)
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143.3

141.9
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61.7

20.7

12.7

2.1

1.7

150

µg BACPT Trapped in HSAPs
Figure 5.8. Final BACPT-HSAP size compared to the amount of BACPT µg added to the
preparation solution for individual samples.

It is speculated that particle formation dynamics may play a role in loading. More evidence
that the particles size did not change in correlation to increasing amounts of BACPT present is
shown in Figure 5.8; where the size consistency of BACPT-HSAPs is not effected by the drug
mass trapped inside them, with all particles remaining within 211 to 270 nm diameter when
loaded with 1.7 to 258 µg of BACPT. Taking that into consideration, one explanation for the
percentage-based loading of the particles could be that some geographical section of the formed
HSAP contains HSA which is available for drug binding and another portion of the HSAP
contains HSA which is less capable of drug binding due to conformational changes responsible
for the consistent sizing. That theory would have to be explored further to indicate a definitive
answer.
Some researchers have concluded that fluorescence should be used for quantitation of
camptothecins, especially after exposure to HSA.109 Our own experience using HPLC for
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BACPT analysis corroborated with this conclusion that intricate methodology is necessary for
precise analysis.
5.4.3

Determination of Loading Efficiency of BACPT via Fluorescence Spectroscopy

In an effort to see how the structure of BACPT might be changing over time and to better
quantitate loading efficiency, the sample supernatants and washes were analyzed by fluorescence
spectroscopy and compared to a set of standards that were created at the same time. In an effort
to spare resources, we did not investigate this loading maximum, as it has been shown that
BACPT concentrations in the μmol/L range have been sufficient for cell death. 52, 55
Previous literature has shown that the fluorescence of BACPT does change over time, with
conversion to the carboxylate form capable of happening in as little as 30 minutes in water.
Since the particle solution we have used is 80% ethanol, the conversion was expected to happen
more slowly, however it would still likely take place. A standard solution of 0.001 mg/mL
BACPT in 50:50 water:ethanol was created and fluorescence spectroscopy was done with
excitation at 403 nm with emission collected at 500 nm to monitor fluorescence changes. Twenty
four hours later, the same standard solution was analyzed with fluorescence spectroscopy again.
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Figure 5.9. Excitation and emission of 0.001 mg/mL solution of BACPT in 1:3 water:ethanol
(solid lines) 30 minutes after creation and (dashed lines) 24 hours later.

Figure 5.9 shows the excitation and emission spectrum of the BACPT standard within 30
minutes after creation (solid lines) and 24 hours later (dashed lines). It is evident in the graph that
there exists some decrease and shift in the fluorescence emission of the BACPT standard after
only 24 hours in 50:50 water:ethanol. This would make it difficult to compare a sample
supernatant to a standard of known concentration if the age of the solutions are different. In order
to find out if the fluorescence change was concentration dependent, we prepared a set of
standards of equal volume (all in 50:50 water:ethanol), but of varying concentrations of BACPT
and measured the fluorescence intensity. Then, the standards were allowed to sit in the dark for
24 hours and fluorescence intensity measurements were taken again. The fluorescence intensity
of the standards measured within 30 minutes of creation and 24 hours later changed at the same
rate.
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Figure 5.10. Fluorescence Emission points for a series of 3 standard solutions (0.00001, 0.0001
and 0.001 mg/mL) of BACPT in 1:3 water ethanol solvent (Solid trend line and diamond data
point markers) within 30 minutes after creation and (Dashed lines) 24 hours later.

Figure 5.10 represents calibration curves for the standards within 30 minutes (solid trend
line) of creation and 24 hours later (dashed trend line). As seen in the graph, the standards
change at the same rate, as shown by the linearity of the points. This means that the BACPT may
in fact be changing to the carboxylate form (assuming this isn’t just representative of a loss of
fluorescence in general), however the change is not dependent on drug concentration. Therefore,
we can use fluorescence to analyze total BACPT present in the sample supernatant and washes,
regardless of which form the BACPT is in, as long as the standards are created at the same time
as the samples.
Of course, sample analysis sooner rather than later post preparation is preferred. However
with the preparation process calling for at least 12 hours of formation and cross-linking time,
there must be some lag in analysis time. The emission spectra for carboxylate and lactone forms
of BACPT are so similar, that it can be difficult to tell them apart, as they both excite at 403 nm.
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Figure 5.11. Relationship between mg BACPT added to formation solution and (solid line) µg
BACPT trapped in the particle batch and (dashed line) % of BACPT loading efficiency. The
measurements shown are the average calculated values for the preparation types BACPT-HSAP2, BACPT-HSAP-3 and BACPT-HSAP-4.

Upon fluorescence analysis of BACPT-HSAPs prepared by either, BACPT-HSAP-2,
BACPT-HSAP-3 or BACPT-HSAP-4, it can be seen in Figure 5.11 that there is a relationship
between µg of BACPT added to the preparation solution and µg of BACPT that becomes
encased in the HSAPs, just as in the case of HPLC analysis.
Upon investigation of the percent of BACPT trapped versus the µg of BACPT added to the
preparation solution, a discrepancy from HPLC becomes evident. When utilizing fluorescence
for quantitation, the calculated average loading is reduced to 82 μg from 112 μg (as determined
via HPLC) for a sample created with 500 μg of BACPT added to initial preparation (method
BACPT-HSAP-4) While 82 μg mg is inside of the calculated error for the BACPT-HSAP-4
created batches, it is still worth considering that the HPLC method separated the carboxylate and
lactone forms of BACPT differently in the standard solutions due to the water in the mobile
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phase; possibly causing it to appear as though there was more BACPT present in the samples
when compared to the peak areas of older standard solutions.
Regardless of the quantitation method, there is evidence in both cases that BACPT is indeed
becoming trapped within the HSAPs. The real test of whether or not the encapsulated BACPT is
still effective at killing cancer cells was yet to be seen, therefore cell studies were done to
determine that the combative properties of the BACPT had not been lost.
This means that the BACPT may in fact be changing to the carboxylate form (assuming this
isn’t just representative of a loss of fluorescence in general), however the change is not
dependent on drug concentration. Therefore, fluorescence could be used to analyze total BACPT
present in the sample supernatants and washes, regardless of which form the BACPT is in, as
long as the standards are created at the same time as the samples. Of course, sample analysis
sooner rather than later post preparation is preferred. However with the preparation process
calling for at least 12 hours of formation and cross-linking time, there must be some lag in
analysis time.
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Figure 5.12. Relationship between µg BACPT added to the sample formation solution and the
average µg BACPT trapped in the BACPT-HSAPs.

Upon analysis of BACPT-HSAPs prepared with either, 100, 250 or 500 µg BACPT, it can be
seen in Figure 5.12 that 13 ± 7, 44 ± 10 and 82 ± 20 µg BACPT is entrapped, respectively. There
is a linear relationship between µg of BACPT added to the preparation solution and µg of
BACPT that becomes encased in the HSAPs. There is evidence that BACPT is indeed becoming
trapped within the HSAPs. The real test of whether or not the encapsulated BACPT is still
effective at killing cancer cells was yet to be seen, therefore cell studies were done to determine
that the combative properties of the BACPT had not been lost.
5.4.4

Human Sarcoma (CL) in vitro Cytotoxicity of Unloaded-HSAPs & BACPT-HSAPs

Using untreated human sarcoma cancer cells (CL) as a cell control and Unloaded-HSAPs as a
particle control, the BACPT-HSAPs were tested for visual cytotoxicity. In order to test the
cytotoxicity of the unloaded-HSAPs, they were delivered at a concentration of ~9.1 X 1011
HSAPs/ mL to the cells (theoretical particle creation calculation based on all 20 mg of HSA
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forming 200 nm diameter spherical particles with density of 1.3 g/cm3). Figure 5.13a shows the
CL cell control with no particles added, where cells are vital and continuing to grow and
multiply. Figure 5.13b shows some inhibition of cell growth when unloaded HSAPs were added
where most cells were inhibited to a rounded state without much multiplication, however some
cells were still growing. With this high HSAP concentration, there is an increase in what seems
to be aggregation of the particles around the cancer cells, causing the growth inhibition, however
there doesn’t appear to be any cell death.
This inhibition could be considered a positive result as it would confirm that the HSA
particles are indeed attracted to and attaching themselves onto human cancer cells. This growth
inhibition may not be an accurate reflection of what would happen in an in vivo scenario, when
the HSAPs are not simply deposited on top of a few cells, but are allowed to distribute through a
tumor site.

b.

a.

Figure 5.13. Optical Image of Human Sarcoma Cells (CL) with A) no nanoparticles added. B)
unloaded-HSAPs added

95

BACPT-HSAPs were tested for visual cytotoxicity as well using CELL METHOD 1. A
BACPT-HSAP-4 preparation method yielded a particle batch with ~124 µg of BACPT trapped
within 20 mg of HSAPs; the entire batch was dispersed into 4 mL of water and ultrasonicated. A
BACPT-HSAP solution was diluted further in RPMI, yielding an effective BACPT drug dose
delivered to the cell of approximately 15.5 ng. Decreased BACPT-HSAP amounts were initially
chosen in order to not overwhelm the cells with particles, but to test the combative properties of
the drug. Notably, in Figure 5.14, the lesser dose condition shows growth inhibition, cell
blebbing and signs of apoptosis.

Figure 5.14. Optical image of Human Sarcoma Cells (CL) with a diluted dose of BACPTHSANPs. Approximately 15.5 ng BACPT delivered.

This low-dose anticancer activity was an extremely hopeful result. It is in-line with
previous studies which have found that at low concentrations, J-type aggregates are formed by
stacking of the BACPT rings, resulting in self- aggregation which prevents hydrolysis of the
lactone ring at neutral pH, assuming they have come completely away from the HSA. 102 In one
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study, BACPT showed the most potency when compared to six other classes of cancer drugs,
including gemcitabine, the current gold standard for treatment of pancreatic cancer. BACPT was
sixfold more potent than the gemcitabine and two to four logs more active than the other five
drugs: vinorelbine, etoposide, dasatinib, 5-flurouracil and 5-azacytidine. 55
5.4.5

Cytotoxicity of BACPT-HSAPs of Varying Concentrations on Human Sarcoma
(CL)
Using CELL METHOD 2, BACPT-HSAPs were delivered to the CL cells without

dilution, but with varying concentrations of drug loaded within; with overall higher drug
dosages. Since the BACPT-HSAP solution aliquot delivered to the cells theoretically contains
upwards of 100 billion particles, it could be hard to see the resulting vital state of the cells. It was
decided that the cytotoxicity test would include incubating the cells which were stuck to the well
plates with the particles, then removing the RPMI media, along with the particles and dead cells.
Three samples of BACPT-HSAPs were created via preparation methods BACPT-HSAP2, BACPT-HSAP-3 and BACPT-HSAP-4 with varying amounts of BACPT encapsulated within
them (as determined via fluorescence): ~20, 37 and 74 µg, respectively. Without dilution, 0.1 mL
of the BACPT-HSAPs were each delivered to separate CL cell samples in replicate, resulting in
~2, 3.7 or 7.4 µg of encapsulated BACPT actually delivered to the cell well. No particles were
added to the cell control.
Figure 5.15 shows the cell plates after the particles and dead cells were removed. Figure
5.15a shows that the untreated cells were able to thrive and continue to grow, even after washing.
Cells treated with ~2, 3.7 and 7.4 µg (Figures 5.15b, 5.15c and 5.15d, respectively) show
progressively less viable cells after treatment and washing; with Figure 5.15d having no cells
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visible in the center of the well. This indicates that as the dosage of BACPT increased, more CL
cells were killed, became unstuck from the plate, and were washed away.
a.

b.

c.

d.

Figure 5.15. Optical image of Human Sarcoma Cells (CL) with (a) non-treated control cells and
cells treated with a dose of BACPT-HSAPs containing (b) 2 µg, (c) 3.7 µg and (d) 7.4 µg of
BACPT.

It becomes obvious that these doses of BACPT are in fact effective for killing human
sarcoma cancer cells in vitro. This proves that the amount of BACPT-HSAPs is not responsible
for overwhelming the cells and killing them, but it is the concentration of the BACPT which is
responsible for cell death. According to these findings that BACPT-HSAPs (likely with BACPT
present in the carboxylate form) are effective at killing human sarcoma cancer cells.
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Decidedly, in vivo work on an active animal model will give further insight into the
effectiveness of BACPT-HSAPs under dynamic, realistic tumor conditions. Such in vivo
experiments must be done to confirm cell growth and complete cytotoxicity. Also, the
atmospherically oxygenated environment (20-21% oxygen) of the in vitro cell work presented
here is not reflective of the hypoxic environment of a tumor site (1-2% oxygen), which causes
the acidic extracellular environment. Since the cytotoxicity of most anticancer drugs is extremely
pH dependent both in vitro and in vivo, a dynamic in vivo experiment is vital for further
studies.58
5.4.6

Formation and Characterization of CPT-HSANPs

In an effort to compare the HSAP loading efficiency of the 7 and 10 carbon substituted
BACPT with the parent drug camptothecin, CPT-HSAPs were prepared and analyzed. The CPT
has a low solubility of < 1mg/ mL in ethanol. 110 Therefore, the camptothecin was dissolved in a
mixture of 50:50 chloroform: ethanol. Subsequent dilutions for the preparation of standards
were done with 3:2 ethanol: water. Via dynamic light scattering, the CPT-HSAPs were found to
have an average diameter of 475 ± 15 nm. These particles are larger than the BACPT-HSAPs,
however they may have just been more susceptible to aggregation, due to the average zeta
potential value being -12 ± 4 mV. Either the CPT facilitates larger particle formation or it causes
more attractive interactions between particles.
5.4.7

Determination of Loading Efficiency of CPT

To determine the loading efficiency of CPT into the CPT-HSAPs, HPLC was chosen first
again as a quantitative method of analysis. Using a 40: 60 acetonitrile: water mobile phase, the
CPT standards produced an analyte peak at 3.1 minutes. A standard solution of 0.01 mg CPT/ ml
solvent (1:3 water: ethanol) was analyzed within 30 minutes of preparation and found to have a
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peak area of 683 at 3.1 minutes. The same standards was analyzed 24 hours later on HPLC and
found to have a significantly reduced peak area at 3.1 minutes. Aside from the decrease at 3.1
minutes, the aged standard showed new peaks at 0.9 minutes and 6.2 minutes.
It was thought that peaks appearing at 0.9 to 1.2 min could be the open ringed, carboxylate
version of the camptothecin molecules eluting from the column quickly in the mobile phase. The
peak appearing at roughly 6.2 minutes was actually thought to be a lower concentration of the
lactone version of the CPT. This is thought to be the portion of the lactone-CPT that is in water,
thus lingering on the column longer; with only 40% acetonitrile not having the solvency strength
to push it thought the column as quickly. Interestingly enough, the remaining peak at 3.1
minutes, which is the time at which the CPT elutes in a freshly made CPT solution is thought to
be the lactone-CPT stacking upon itself in the ethanol present in the solvent. 102 The stacking of
the molecules cause an elution time slower than that of the carboxylate version being pulled off
by the acetonitrile, but slower than the lactone version in water.
When a solution of 0.001 mg of CPT in 1 mL of ethanol only was created and analyzed on
HPLC, the analyte eluted at ~3.0 minutes with a peak area of 350 mA.U. Twenty four hours
later, the standard solution eluted at the same time, but with a peak area of only 72 mA.U. There
was not a large peak increase at 0.9 or 6.2 minutes to account for this elution loss at 3.0 minutes.
Therefore, the molecule was likely sticking to the column, as the acetonitrile concentration was
not strong enough to elute the CPT as it had when the sample was fresh.
More experimentation would need to be done to confirm the sample breakdown hypothesis,
proving information about the change in conformational states of the CPT over time. However,
for our purposes in this project, HPLC would not serve as an efficient method of analysis, as the
solvent was playing too big of a role in the temporal integrity of the sample.
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Again, fluorescence was chosen as the secondary means of quantitative analysis of the CPT
washed off of the CPT-HSAPs. Although, contrary to the case of BACPT, fluorescence
measurements for CPT quantitation turned out to be even more elusive and sporadic. Samples of
CPT-HSAPs were created for dosing the CL human sarcoma cell line, so the loading quantitation
was attempted. The initial sample preparation solution for the treatment batch was made with 0.5
mg of CPT, so batches of CPT-HSAPs were created with 0.1, 0.25 and 0.5 mg CPT in order to
find a loading trend.
Upon fluorescence spectroscopy, with excitation maximum at 358 nm and emission at 428
nm, it was found that every batch of CPT-HSAPs created with carrying starting masses of CPT
gave loading efficiencies of over 100%, despite have linear calibration curves for reference. This
is not possible, so further fluorescence studies on standard solutions of CPT were performed.
First, standards of 0.0005 mg CPT/ mL solvent were created in chloroform and ethanol only
and in chloroform, ethanol and water (to more closely mimic the particle preparation matrix).
The CPT solutions in chloroform and ethanol showed a decrease in fluorescence intensity over
72 hours, as shown by Figure 5.16.
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Figure 5.16. Fluorescence excitation and emission spectra of 0.005 mg CPT/ mL in ethanol and
chloroform, immediately after preparation and 72 hours later.

Notably, when less than 1% water was present in the solvent matrix, the CPT fluorescence
intensity remained the same for 72 hours (as did the excitation intensity), as seen in Figure 4.17.
600

EX CPT EtOH:Chloroform:Water
72 Hr_EX CPT EtOH:Chloroform:Water
EM CPT EtOH:Chloroform:Water

500

72 Hr_EM CPT EtOH:Chloroform:Water
400
300
200
100
0
300

350

400

450

500

550

600

650

Figure 5.17. Fluorescence excitation and emission spectra of 0.005 mg CPT/ mL in ethanol,
chloroform and 0.27% water, immediately after preparation and 72 hours later.
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The reason the fluorescence intensity was not effected over 72 hours when water was present
is not known. What is noticeable is that the solvent effects caused a difference in initial
fluorescence intensity of roughly 598 for the chloroform:ethanol standard and roughly 558 for
the standard containing as little as less than 1% water in the solvent matrix.
Because the sample matrix never contains that little water (and initial supernatants and
subsequent washes even contain varying amount of water), another solution of 0.0005 mg CPT/
mL solvent was created with 25 % water present along with the ethanol:chloroform matrix. As
seen in Figure 5.18, this time, the fluorescence intensity of the solution did decrease over 24
hours and continued to decrease as far as 9 days later.
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Figure 5.18. Fluorescence excitation and emission spectra of 0.005 mg CPT/ mL in ethanol,
chloroform and 25% water, immediately after preparation, 24 hours later and 9 Days later.

To see whether this decrease was concentration dependent, a set of standards of varying
concentrations were made with the more realistic solvent matrix of 25% water and 75%
ethanol:chloroform to study the fluorescence intensity change over 24 hours. Figure 5.19 shows
the decline in CPT fluorescence intensity over 24 hours.
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Figure 5.19. Fluorescence emission calibration curves for CPT standards with concentrations of
0.00001, 0.0001 and 0.001 mg CPT/ mL in ethanol, chloroform and 25% water, immediately
after preparation and 24 hours later.

Although on first glance, the loss of fluorescence intensity does not seem to be concentration
dependent, as noted by the linearity of the standards’ fluorescence change over time, Observing
the actual fluorescence intensity values versus the concentration values (in Table 5.4) of the
solutions gives another perspective:
Table 5.4. Max fluorescence intensity for CPT solutions upon creation and 24 hours later.
Concentration
of CPT
(mg/mL)
0.00001
0.0001
0.001

MAX
Fluorescence
Intensity on
DAY 1
4.6
11.2
330.7

MAX
Fluorescence
Intensity on
DAY 2
1.7
11.1
109.3

At the lowest concentration of 0.00001 mg/mL, the CPT fluorescence intensity decreased by
36%, but remained constant for the 0.0001 mg/mL CPT standard. Finally, the 0.001 mg/mL
experienced a 33% decreased in fluorescence intensity. Either the 0.0001 mg/mL CPT solution
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was an anomaly and kept its quantum efficiency or there was some error in the analysis.
Regardless, the fluorescence intensity changes for the camptothecin are difficult to fully assess
and would require more time and effort to comprehensively explain the kinetics of the opening
of the lactone ring based on varying concentrations and solvent effects.
Finally, the loss in fluorescence intensity is greater for CPT than BACPT over a twenty four
hour period and is likely causing the sample supernatants to seem as though they contain more
CPT than what was originally added to the preparation solution when compared to a decaying set
of standards. It is a possibility that the HSA could be protecting the CPT from decaying s fast in
the sample matrix in some way, but more studies would have to be performed to prove that
theory.
5.4.8

Cytotoxicity of CPT-HSAPs of Varying Concentrations on Human Sarcoma (CL)

Despite the trouble with completely and accurately quantifying the amount of CPT trapped
within the CPT-HSAPs, the particles were still tested for cytotoxicity against the human sarcoma
“CL” cell line. A 20 µL aliquot of the final particle sample was added to a well containing the
CL cells and termed a “high dose” of the particles. Figure 5.20 shows the cytotoxic effects of the
particles. When compared to the human sarcoma CL control from Figure 5.13a and the HSAP
control from Figure 5.13b, it is evident that these CPT-HSAPs cause cell death.
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Figure 5.20. Optical Image of Human Sarcoma Cells (CL) treated with a “low dose” of CPTHSANPs.

When a 20 µL aliquot of 25% diluted CPT-HSAPs was added to the CL cells, the trial
was termed a “low dose” particle delivery. Figure 5.21 shows the human sarcoma CL cells after
incubation with a low dose of the CPT particles. Again, even when the particles were diluted,
they still caused cell death. Unfortunately, due to the quantitation issues surrounding the CPT, it
is not known what the actual mass of drug present in the particle sample was. Without that
knowledge and a valid method to continue quantitation, subsequent release studies could not be
performed to try to determine what mass of camptothecin was responsible for causing this
successful cytotoxicity result.
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Figure 5.21. Optical image of Human Sarcoma Cells (CL) treated with a “low dose” of CPTHSANPs.
5.5 Conclusions
This research has shown that the loading BACPT and CPT into HSAPs is possible with
controlled particle size within 200-300 nm for the BACPT-HSAPs and 400-500 nm for the CPTHSAPs. The resulting BACPT-HSAPs are capable of encapsulation efficiency of at least up to
21%. Moreover, the BACPT-HSAPs are visually cytotoxic to human sarcoma cancer cells down
to a 15 ng dose, despite ideas that BACPT becomes irreversibly bound to HSA and subsequently
medicinally inactive. Further in vivo experiments need to be done to determine whether
BACPT-HSAPs are an effective delivery mechanism for BACPT in an active tumor site and to
determine whether there is a concentration of BACPT-HSAPs that is effective at delivering the
drug in low enough concentrations that a patient’s organs and healthy cells are not at risk.
Unfortunately, the CPT loading quantitation could not be determined with either HPLC
or fluorescence spectroscopy due to the water in the mobile phase during HPLC analysis and the
erratic effects of the water in the sample preparation on the fluorescence emission of CPT.
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Chapter 6 Summary and Conclusions
In Chapter 2, composite AuNP-HSAPs, AuNS-HSAPs, and AuNR-HSAPs were successfully
prepared as a proof of concept to show that these composite particles can serve as platforms for
preparing new drug therapies. This research has shown that size-controlled encasement of these
gold nanomaterials into larger (100-300 nm) HSAPs is possible via a desolvation and
crosslinking process. This study served as the basis for the rest of the work. Proving gold
nanomaterials could be encased in a bio-friendly protein shell which is large enough to load
sufficient drug was important. Moreover, the same preparation parameter manipulations that
allow for controllable particle size of medicinally useful HSAPs are in operation when the
procedure is conducted with gold nanomaterials present. What we were left with was a template
for future custom loading and surface functionalization.
In Chapter 3, the first assessment of simultaneous loading of gold nanomaterials and proven
chemotherapeutic drug proved successful with the formation of PAC-AuNR-HSAPs. In addition
to the loading capabilities, the photothermally active function of the gold was not lost after
forming thiol bonds with the HSA or with any interaction with the drug. The combined approach
will allow killing of cancer cells by both hyperthermia and localized chemotherapy treatment and
is more likely to eliminate all cancer cells.
We saw that the level of heating could be controlled with the amount of gold present in the
particles and the ‘doses’ of each preparation type. This is important because it allows for
controlled heating, where a tumor in a particularly fragile site may not be able to receive
complete ablation, however slight heating of the particles may result in an increase in drug
uptake over time. The exact number of gold nanoparticles loaded into each HSAP to achieve
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effective hyperthermic treatment safe enough for in vivo treatment is not yet known, but is the
subject of ongoing studies, as is a step-wise increase in heating temperatures.
In Chapter 4, hybrid AuNR-HSAPs were successfully prepared for in vitro studies and
showed more controllable size distributions when more protein is added to the preparation vial.
The particles were able to heat to necessary temperatures in order to cause renal cell carcinoma
death, but careful consideration of the particle dose has to be maintained in order to not
overwhelm the cells without irradiation. Fluorescence uptake studies confirmed that the AuNRHSAPs are being taken up into the cancer cells, but are not entering the cell nuclei.
Functionalizing the surface of the HSAPs with disease-specific targeting ligands may lead to
even more effective delivery of cancer therapies to the site of the disease, boosting effectiveness
and reducing damage to healthy tissue 42
Finally, in Chapter 5, the research has shown that the loading BACPT and CPT into HSAPs
is possible with controlled particle size and resulting BACPT-HSAPs are capable of
encapsulation efficiency of at least up to 21%. Moreover, the BACPT-HSAPs are visually
cytotoxic to human sarcoma cancer cells down to a 15 ng dose, despite ideas that BACPT
becomes irreversibly bound to HSA and subsequently medicinally inactive. CPT is also toxic to
human sarcoma cells but the necessary loaded drug amount is not known. HPLC analysis proved
unhelpful in assessing loading efficiency of the drugs due to the impeding mobile phase on the
stability of the drug structure.
Further in vivo experiments need to be done to determine whether BACPT-HSAPs are an
effective delivery mechanism for BACPT in an active tumor site and to determine whether there
is a concentration of BACPT-HSAPs that is effective at delivering the drug in low enough
concentrations that a patient’s organs and healthy cells are not at risk.
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Currently on-going studies include the loading of sorafenib (SRF), an angiogenesis inhibitor,
into AuNR-HSAPs for use on renal cell carcinoma in vitro. Animal studies are currently being
arranged with our Tulane collaboration to assess the photothermal therapy capabilities of the
AuNR-HSAPs as well as the hybrid effects of the sorafenib-loaded SRF-AuNR-HSAPs. Future
studies will also include surface functionalization of targeting ligands to direct the hybrid
particles to the tumor site as well as increase particle uptake.
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